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ABSTRACT
The United States is facing an unprecedented crisis of drug overdose and poisoning deaths.
In this dissertation, we studied three different aspects of opioid use disorder and healthrelated outcomes using routinely collected data.
Manuscript 1: We designed a cross-sectional study to evaluate the association between
early buprenorphine-naloxone initiation (within 90 days after the diagnosis of opioid use
disorder) and health-related outcomes among insured adults with opioid use disorder in the
United States from 2010 to 2018. Generalized linear models with multiple imputation to
account for missing data were applied to estimate the association and adjust for selfreported socioeconomic status, comorbidities, and concomitant medications. We found
that timely buprenorphine-naloxone initiation was associated with a reduced occurrence

of opioid overdose and a statistically significant reduction in opioid overdose-related
emergency department visits and costs.
Manuscript 2: We designed a retrospective study to evaluate the association between timevarying buprenorphine-naloxone prescribing and subsequent opioid overdose or death
among insured adults with opioid use disorder in the United States from 2010 to 2017. We

fit a marginal structural model using inverse probability weights to account for
measured baseline and time-varying confounders, as well as selection bias due to
possibly informative lost-to-follow-up. We found that continuously receiving
buprenorphine-naloxone was associated with reduced risk of opioid overdose and allcause mortality.
Manuscript 3: We designed a retrospective study to estimate the direct and disseminated
effects of buprenorphine-naloxone prescribing on subsequent health-related outcomes

(opioid overdose, death, emergency department visit, hospitalization) among insured adults
with opioid use disorder in the United States between from 2010 to 2017. We used both an
inverse probability weighted estimator and a stabilized estimator to estimate the causal

effects of buprenorphine-naloxone with possible spillover or interference. We found
that showed that being prescribed buprenorphine-naloxone was protective against
opioid overdose, death, and hospitalization during a two-year follow-up period.
Interestingly, among untreated patients, being in a cluster with 67% coverage of the
medication (i.e., 67% of patients in the cluster were treated) was associated with a
lower risk of opioid overdose and death than being in a cluster with lower coverage at
33% or 50%.
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PREFACE
This dissertation is written in the manuscript format and is comprised of three
manuscripts studying the medications for opioid use disorder and health-related
outcomes.
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and cost among patients with opioid use disorder in the US, 2010 – 2018
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Abstract:

Background: Although the effectiveness of buprenorphine-naloxone (BUP-NX) has been
established, real-world evidence on the benefits of early treatment initiation is lacking.

Objective: To evaluate the association between early BUP-NX initiation and healthrelated outcomes among insured adults with newly diagnosed opioid use disorder
(OUD).

Methods: We conducted a cross-sectional analysis using the Optum’s de-identified
Clinformatics® Data Mart Database from 2010 to 2018. Patients who initiated BUP-NX
within 30 days of OUD diagnosis were classified as early initiators, otherwise as late
initiators. Outcomes included opioid overdose, opioid overdose-related emergency
department (ED) visits, and all-cause healthcare cost during one-year of follow-up. We
employed generalized linear models to compare outcomes between early and late
initiators, adjusting for baseline covariates and accounting for missing data using
multiple imputation.

Results: A total of 8,388 patients with OUD were identified; mean age, 39.9 years; 36%
were female; and 67.56% were early initiators. Early initiators had an estimated 42%
lower rate of opioid overdose (adjusted rate ratio (aRR) = 0.58; 95% confidence interval
(CI): 0.45, 0.74); 51% lower rate of opioid overdose-related ED visits (aRR = 0.49; 95% CI:
2

0.39, 0.60); 48% lower risk of opioid overdose (adjusted odds ratio= 0.52; 95% CI: 0.41,
0.66); and 31% lower total healthcare cost (adjusted cost ratio = 0.69; 95% CI: 0.66,
0.72), compared to late initiators.

Conclusion: Compared to late BUP-NX initiation, the early initiation was associated with
a lower risk of opioid overdose and opioid overdose-related ED visits, and reduced total
healthcare cost among insured adult patients with OUD.

3

Introduction

The U.S. Department of Health & Human Services declared opioid use disorder (OUD) a
national public health crisis in 2015 (1, 2), attracting renewed scientific interest in
identifying implementation strategies to address the opioid epidemic. Several studies
have shown that OUD is associated with elevated morbidity, overdose-related mortality,
and other adverse health conditions (3-5). A systematic review and meta-analysis of 58
cohort studies of people living with OUD found a pooled all-cause crude mortality rate
of 20.9 per 1000 person-years and a pooled standard mortality ratio of 14.7, with opioid
overdose being the most common cause of death (6). This crisis is worsening with the
presence of the COVID-19 pandemic(7-9). Based on the available data, drug overdose
deaths started to increase from 2020 March (10).

It is estimated that there are more than 2 million people living with OUD in the US and
the total cost of the opioid crisis including, direct, indirect, and lost productivity, has
been rising dramatically in recent years. For example, the total cost of OUD care
increased from 43.2 billion in 2009 to 78.5 billion in 2013 (11, 12). The increased cost of
OUD and opioid-related overdose deaths in the US has drawn more attention on the
need to expand access to medications for opioid use disorder (MOUD). The US Food and
Drug Administration (FDA) has approved buprenorphine (with/without naloxone),
methadone, and injectable naltrexone for the treatment of OUD (13). The American
Society of Addiction Medicine’s updated national practice guidelines recommends the
4

use of one of these three medications for OUD care (14). Although long-term treatment
of OUD has shown great promise in curbing the opioid overdose crisis, few patients are
initiated or maintained on long-term treatment after diagnosis. For example, from 2009
to 2013, only 1 in 5 patients living with OUD received any form of treatment (15). As a
result, access to MOUD continues to be limited for many people living with OUD due to
provider, pharmacy, geographic, regulatory, and financial barriers (16-19).

Of the 3 medications (buprenorphine, naltrexone, methadone) approved for OUD,
buprenorphine-naloxone (BUP-NX) is widely viewed as offering the greatest opportunity
for expanding access to medication treatment. Naltrexone initiation often requires
detoxification and an opioid-free period (20, 21), and higher induction failure rates have
been observed compared to buprenorphine (with or without naloxone) (22).
Furthermore, a recent cohort study showed that all-cause and opioid-related mortality
rates during the first four-week after treatment initiation were higher among patients
treated with methadone as compared to those who received buprenorphine (with or
without naloxone): adjusted all-cause mortality RR: 2.17, 95% CI: 1.29, 3.76; adjusted
opioid-related mortality RR: 7.61, 95% CI: 1.80, 31.94 (23). Current OUD clinical
management guidelines recommend BUP-NX as the recommended treatment (24, 25).

Several studies have investigated the relationship between MOUD and all-cause
mortality, but very few have examined the association between timely initiation of
treatment and health-related outcomes. A recent observational study found that timely
5

initiation of MOUD (i.e., within 3-month after OUD diagnosis) was associated with a
higher rate of retention on treatment compared to the use of behavioral health services
alone among youths (ages 13 -22) with OUD (26). One randomized clinical trial
compared immediate BUP-NX initiation in the emergency department (ED) with brief
behavioral intervention and/or referral without initiating MOUD (27). Initiation of BUPNX in the ED was found to reduce self-reported illicit drug use and use of inpatient
services during a 30-day follow-up period, compared to patients who only received the
brief behavioral intervention and/or referral for treatment. In another small randomized
trial, early treatment with buprenorphine (initiated after randomization) resulted in
significant reductions in illegal opioid use compared to those who initiated treatment
later at 4, 8, and 12 weeks, respectively (28). These studies suggest that early initiation
of BUP-NX may be the recommended OUD management strategy for most patients (14).
However, the relationship between early BUP-NX initiation and health-related outcomes
(e.g., opioid overdose episodes, healthcare utilization, and cost) has not yet been well
studied. This study examined the association between early BUP-NX initiation and
health-related outcomes, including opioid overdose, opioid overdose-related ED visits,
and total healthcare cost, among insured adult patients living with OUD in the United
States from 2010 to 2018.

Study Design

6

We conducted a cross-sectional analysis using healthcare claims from the Optum’s deidentified Clinformatics® Data Mart Database (OptumInsight, Eden Prairie, MN). The
data spanned the period from January 1, 2010 through December 31, 2018. To create
the study sample, the following eligibility criteria were applied to identify all adults with
a diagnosis of OUD: 1) at least two separate outpatient claims within 3 months of each
other or one inpatient claim for OUD as the primary or secondary diagnosis using the
International Classification of Diseases, 9th and 10th Revision, Clinical Modification (ICD9/10-CM) code (Appendix A Table 1) (26, 29, 30); 2) at least one year of continuous
enrollment before the first eligible OUD diagnosis (index date); 3) at least one year of
continuous follow-up after the index date; 4) at least 18 years old as of the index date;
5) initiate BUP-NX during the one-year following the index OUD diagnosis. The baseline
period was used to ascertain demographic and medical information. We defined the
date of the first observed OUD diagnosis as the start of follow-up. Both the exposure
and the outcome were defined during the follow-up (Figure 1). The creation of the
analytic sample is shown in Figure 2.

Receipt of BUP-NX was identified using pharmacy claims by brand or generic names.
Mono-ingredient buprenorphine was not considered as exposure. Because there was no
information about the formulation and the indication and we were not able to
distinguish whether it was prescribed for pain or OUD management. Early BUP-NX
initiation was defined as receipt of BUP-NX within 30 days after the index date. Patients
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who initiated BUP-NX after 30 days of the index OUD diagnosis were classified as late
initiators.

The study had four main outcomes: 1) the number of opioid overdose-related ED visits;
2) any occurrence of opioid overdose; 3) counts of opioid overdose episodes, and 4)
total healthcare cost (including inpatient, outpatient, and prescription cost) during the
one-year period following OUD diagnosis. The occurrence of an opioid overdose was
measured in terms of the number of opioid overdoses episodes and as a binary indicator
of whether a patient experienced an opioid overdose or not. Opioid overdose was
identified using ICD-9/10 codes in inpatient and outpatient claims. Opioid overdose
claims separated by at least 7 days were considered different overdose episodes
(Appendix A Table 1). To identify ED visits, we used the Yale ED identification algorithm,
which utilizes the Healthcare Common Procedure Coding System (HCPCS) codes,
revenue codes, and place of service codes in the database (31, 32). Total healthcare
costs in the year following the index date were defined and computed as the sum of
reimbursed costs paid by the health plan for all inpatient and outpatient medical claims
and outpatient pharmacy files. The cost was adjusted for inflation to the 2018 US dollar
using the Consumer Price Index inflation calculator from the Bureau of Labor Statistics
(33).

Sociodemographic covariates included age at OUD diagnosis, gender, type of insurance
(commercial or Medicare Advantage), type of health plan, and self-reported
8

socioeconomic status (SES). Clinical baseline covariates included history of opioid
overdose, history of opioid utilization, opioid polypharmacy, Charlson comorbidity index
(CCI), receipt of methadone and/or naltrexone, daily morphine milligram equivalence
(MME), history of chronic obstructive pulmonary diseases, depression, receipt of
antidepressants, history of alcohol use disorder, and total healthcare cost during the
baseline period (4). Opioid prescription information was converted to daily MME using
standard conversion factors provided by the Centers for Disease Control and Prevention
(CDC) (34). The CCI included 17 different conditions, such as myocardial infarction and
chronic obstructive pulmonary diseases, and it is widely used as a measure of disease
burden (35). The self-reported SES included race, house ownership, educational level,
household income level, household net worth, poverty level, and presence of a child in
the household. Some of the SES data was missing and 58.4% of patients had complete
information (n = 4,899), and the missing pattern was not monotone (Appendix A Table
2). All baseline comorbidities were identified using ICD-9/10-CM from both inpatient
and outpatient records (Appendix A Table 1) (36).

Statistical Methods

Baseline characteristics were summarized by the BUP-NX initiation group. Descriptive
statistics were calculated as mean with standard deviation (SD) for continuous variables
and frequency and percentage for categorical variables. We employed a generalized
linear model (GLM) to compare the outcomes between early BUP-NX initiation and late
9

initiation. The log link with a Poisson distribution was used for count outcomes (i.e.,
number of opioid overdose episodes and number of ED visits); the log link with a gamma
distribution for cost outcome (i.e., total healthcare cost); and the logit link with a
binomial distribution for the binary outcome (37).

We first fit an unadjusted model on the full study sample. Due to the missing data in
self-reported SES, we conducted an adjusted comparison among complete cases
adjusting for SES, comorbidities, and concomitant medications. There was no evidence
of collinearity among baseline variables. To account for missing data in the SES variable,
we employed multiple imputation with a fully conditional specification (FCS), an
imputation approach with continuous and categorical variables. Twenty imputed
datasets with complete information were generated using multiple imputation by FCS.
The exposure status, baseline information, and the outcome were included in the
imputation model. The coefficients estimated by GLM from twenty imputed datasets
were combined, and the confidence intervals were derived using Rubin’s estimator of
the variance (38-40).

Because the results from the imputation may depend on the sequence in which
variables are imputed (41), we conducted a sensitivity analysis with two imputation
sequences: 1) starting from variables that had the most missing value to the ones that
had the least; 2) starting from variables had the least missing value to the most. We also
10

conducted a sensitivity analysis with different definitions of early initiation: as initiation
within 15 or 45 days. In addition, we evaluated the impact of the calendar year (i.e., the
impact of policy changing across the study period) on our result by adding it as a
categorical variable into our models. All statistical analyses were conducted using SAS,
version 9.4 (SAS Institute, Cary, NC), and statistical tests were two-sided and conducted
at the 0.05 significance level. This study was approved by the Institutional Review Board
of the University of Rhode Island.

Results

Overall, 8,388 adult patients were diagnosed with OUD during the study period and
were prescribed BUP-NX sometime during the year following their diagnosis, 5,667
(67.6%) received BUP-NX within 30 days of their OUD diagnosis (i.e., early BUP-NX
initiators), while 2,721 (32.4%) were late initiators (Table 1 and Appendix A Table 3).
Almost two-thirds of the patients were male (64%); a majority were white (68.2%); and
the mean age was 39.9 years (SD = 14.74). More than two-thirds of the patients were
enrolled in commercial health insurance (77.5%), and the rest were enrolled in Medicare
Advantage (22.5%). Based on self-reported SES information, most patients had a
bachelor’s degree or less (81.2%), and about half had a household income of less than
$75,000 (49.2%). More than half of the patients were homeowners (54.9%) and half had
a net worth of more than $250,000 (49.9%). Furthermore, most patients were living
above 400% federal poverty line (FPL) (74.8%) and most lived in a childless home
11

(74.1%). The average CCI at baseline was 0.03 (SD = 1.04), but half of the patients had a
history of chronic pain (49.9%); less than one-third had depression (30.1%); 6.9% had
chronic obstructive pulmonary disease; 6.0% had a documented history of alcohol use
disorder; and 2.9% had a history of opioid overdose. More late initiators (32.6%) had
received benzodiazepine dispensing prior to the OUD diagnosis than early initiators
(28.6%). Usage of benzodiazepine and/or alcohol could delay the initiation of BUP-NX
(42). The average total healthcare utilization cost during the baseline period was
$27,100 (SD = $59,380) (Table 1). Less than 5% of patients had received naltrexone or
methadone for OUD during the follow-up.

Overall, 314 (3.74%) out of 8,388 patients in the study experienced at least one opioid
overdose during the one-year following their OUD diagnosis. Among the early BUP-NX
initiation group, 144 (2.54%) patients had in total 206 opioid overdose episodes.
Meanwhile, among the late BUP-NX initiation group, 170 patients (6.25%) had a total of
220 opioid overdose episodes. The opioid overdose rate was lower among the early
initiators (3.64 per 100 person-year) compared to late initiators (8.09 per 100 personyear). The opioid overdose-related inpatient visit rate was lower among early initiators
compared to late initiators (1 versus 2 per 100 person-year, respectively), but the
average inpatient stay length (among patients who had at least one inpatient admission)
was similar between two groups (4.58 versus 4.42 days per year, respectively). For allcause healthcare utilization, the early initiators had fewer outpatient visits (26.74 visits
per year, SD = 23.60), fewer inpatient admissions (0.56 admissions per year, SD = 1.55),
12

shorter length of inpatient stay (10.91 days per year, SD = 17.20), and fewer ED visits
(2.07 visits per year, SD = 5.06) than late initiators (on average 35.59, SD=29.98
outpatient visits per year; 1.22 [SD = 1.92] inpatient admissions per year; 14.34 [SD =
18.57] days of inpatient stay per year; 3.02 [SD = 6.41] ED visits per year) (Table 2).

Table 3 shows crude average annual costs. The average annual cost of BUP-NX among
early initiators was higher than the mean cost for the late initiators during one-year
after the index OUD diagnosis, $3,637 (SD = $2,987) versus $2,320 (SD= $2,280),
respectively. However, early initiators had a lower average opioid overdose-related
spending on inpatient/outpatient visits during the one year after index OUD diagnosis
than late initiators, $289 and $605, respectively. This was mainly due to fewer number
of opioid overdose-related outpatient visits and inpatient stays. For all-cause spending,
the average annual prescription medication cost was $7,125 (with 51% was due to BUPNX) for the early initiators and $5,803 (with 40% was due to BUP-NX) for the late
initiators. However, the average annual total healthcare utilization cost was lower for
the early initiators compared to late initiators, $34,316 (SD = $63,867) and $55,485 (SD
= $84,874), respectively.

We compared the adjusted healthcare utilization between early BUP-NX initiators and
late initiators by the general linear model combined with multiple imputation.
Compared to the late initiators, the early BUP-NX initiators had a 42% reduction in the
rate of opioid overdose (adjusted relative risk (aRR) = 0.58, 95% confidence interval (CI):
13

0.45, 0.74); 51% reduction in the rate of opioid overdose-related ED visit (aRR = 0.49,
95% CI: 0.39, 0.60); 48% reduction in the odds of opioid overdose (adjusted odds ratio=
0.52, 95% CI: 0.41, 0.66); and 31% less total healthcare cost (adjusted cost ratio (aCR) =
0.69, 95% CI: 0.66, 0.72) (Table 4). The results from sensitivity analyses were
comparable across different definitions of early treatment initiation Appendix A Table
4). The point estimate and the 95% confidence interval were comparable, regardless of
the imputation sequence (Appendix A Table 5). Furthermore, the results were also
consistent across different calendar years (Appendix A Table 6).

Discussion

This cross-sectional study used a large national administrative claim dataset of more
than 50 million insured patients in the United States from 2010 to 2018. The results
provide evidence that buprenorphine-naloxone (BUP-NX) treatment initiation for OUD
within 30 days of the initial OUD diagnosis is associated with clinical and cost benefits
for the patient and the healthcare system as a whole. Early BUP-NX initiation was
associated with a lower risk of opioid overdose, a lower rate of overdose-related ED
visits, and reduced total healthcare cost during the year following an initial OUD
diagnosis, after adjusting for baseline sociodemographic and medical characteristics.

Our findings are consistent with results from other previous studies. For example,
Morgan et al. (43) had shown that active buprenorphine (with or without naloxone)
14

treatment versus interrupted treatment was associated with a lower hazard of overdose
among commercially insured patients with OUD in the US (adjusted hazard ratio = 0.40;
95% CI: 0.35, 0.46). Furthermore, Baser et al. (44) found that patients who received
MOUD had lower total healthcare utilization costs during the 6-month window after
treatment initiation compared to patients with OUD who did not initiate treatment.

Our study fills a critical gap in knowledge and addresses some limitations identified in
prior studies. We successfully identified early initiators from claims data and evaluated
the association between timely BUP-NX initiation and opioid overdose, healthcare
utilization, and cost among insured adult patients with OUD. This study provides
preliminary evidence supporting timely BUP-NX treatment initiation. Our study also
addressed the concern about unmeasured confounding due to SES, a known risk factor
for overdose, by including available information in general linear models with multiple
imputation. We employed generalized linear models with multiple imputation to
account for missing data, leveraging important variables for controlling possible
imbalances between exposure groups. We also conducted a series of sensitivity analyses
to explore the impact of different exposure definitions and the imputation approaches
on the results.

We found that less opioid overdose-related in/outpatient cost was incurred among the
early initiators compared to the late initiators. However, the total opioid overdoserelated cost per patient was higher among the early initiators due, in part, to the
15

incremental cost of BUP-NX treatment. For early initiators, the BUP-NX prescription cost
accounted for 93% of the opioid overdose-related cost among early initiators and 89%
among late initiators. Overall, the adjusted total healthcare utilization cost, including
prescription and in/outpatient cost regardless of disease, was much lower among the
early BUP-NX initiators than late initiators, $34,316 and $55,485, respectively. Baser et
al. (44) also found that the cost of detoxification/rehabilitation and/or provider visits
was 29% higher among untreated patients compared to those who received MOUD. In
another study, immediate BUP-NX initiation in ED was more cost-effective than a brief
behavioral intervention and referral among adult patients with OUD (45).

Our study had some limitations that are common in observational studies using
administrative claims data. Because exposure was not randomly assigned, patient
sociodemographic information and medical history may not be balanced between the
two groups. To address this issue, we used the generalized linear models to adjust for
potential confounders measured at baseline, including gender, SES, and comorbidities.
However, we did not have information about the severity of OUD, illegal drug use,
patient lifestyle, and community distribution of naloxone. Although we used commonly
employed codes from the literature, the sensitivity and specificity of some of the
diagnosis codes have not yet been validated. Because of the cross-sectional design, the
results in this paper do not lend themselves to any causal interpretation. Lastly, we did
not have information on mortality, and the study population was restricted to patients
with commercial insurance or Medicare Advantage.
16

Conclusion

Initiation of buprenorphine-naloxone within 30 days of opioid use disorder diagnosis
was associated with a reduced occurrence of opioid overdose and a significant decrease
in total healthcare utilization and cost during the one-year period following the OUD
diagnosis compared to later initiation. These findings should be considered by clinicians
when assessing potential risks and clinical benefits of initiating BUP-NX among adults
with OUD in routine medical practice. Cohort studies that ensure a temporal ordering
between exposure and outcomes avoid conditioning on post-baseline variables and use
appropriate methods to address confounding are warranted.
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Figure 1 Schematic of the cross-sectional study design
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Figure 2 Flowchart of cohort building based on in/exclusion criteria for a study of
insured adult patients with newly diagnosed opioid use disorder in the United States,
2010 – 2018

19

Table 1 Descriptive summary of baseline medication and comorbidity information of the
analytical sample

Gender, n (%)1
Female
Male
Age (years) at OUD dx, Mean (SD)
Type of insurance, n (%)1
Commercial
Medicare Advantage
Type of health plan, n (%)1
Exclusive provider organization
Health maintenance organization
Point of service
Preferred provider organization
Indemnity or others2
Medical conditions, n (%)
Chronic pain
Depression
Alcohol use disorder
History of opioid overdose
Chronic pulmonary disease
CCI at baseline, Mean (SD)
90 days prior to OUD dx, n (%)
Benzodiazepine
Anti-depressants
180 days prior to OUD dx, n (%)
Multiple opioids Rx
Any opioid Rx
Mean daily MME 180 days prior to OUD
dx, Mean (SD) 3
Daily MME among patients received
prescription opioid 180 days prior to OUD
dx, Mean (SD)3
Medications during the follow-up, n (%)
Naltrexone
Methadone2
Baseline cost ($), Mean (SD)
Outpatient cost
Inpatient cost
Medication cost
ED visit cost
Total healthcare cost

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

2004 (35.4)
3663 (64.6)
40.78 (14.54)

1012 (37.2)
1709 (62.8)
38.07 (15.00)

3016 (36.0)
5372 (64.0)
39.90 (14.74)

4351 (76.8)
1316 (23.2)

2152 (79.1)
569 (20.9)

6503 (77.5)
1885 (22.5)

570 (10.1)
821 (14.5)
3312 (58.4)
263 (4.6)
701 (12.4)

239 (8.8)
429 (15.8)
1636 (60.1)
168 (6.2)
249 (9.2)

809 (9.6)
1250 (14.9)
4948 (59.0)
431 (5.1)
950 (11.3)

2807 (49.5)
1610 (28.4)
284 (5.0)
137 (2.4)
389 (6.9)
0.30 (1.06)

1381 (50.8)
914 (33.6)
216 (7.9)
107 (3.9)
189 (6.9)
0.30 (0.99)

4188 (49.9)
2524 (30.1)
500 (6.0)
244 (2.9)
578 (6.9)
0.30 (1.04)

1618 (28.6)
2119 (37.4)

886 (32.6)
1102 (40.5)

2504 (29.9)
3221 (38.4)

1398 (24.7)
2743 (48.4)
27.5 (52.7)

755 (27.7)
1436 (52.8)
34.0 (59.4)

2153 (25.7)
4179 (49.8)
29.6 (55.0)

56.8 (63.9)

64.4 (68.7)

59.4(65.7)

140 (2.5)
14 (0.2)

195 (7.2)
<11

335 (4.0)
<26

16086 (41823)
4283 (21339)
5490 (13452)
3976 (11113)
25859 (59473)

19963 (38887)
5366 (22457)
4354 (9371)
5231 (13593)
29683 (59115)

17344 (40931)
4634 (21713)
5121 (12289)
4383 (11981)
27100 (59380)

1 Values

of polytomous variables might not sum to 100% due to rounding
Categories were combined, or number was masked due to small cell count
3 Mono-ingredient buprenorphine was included in the MME calculation
rx: prescription; dx: diagnosis; MME: morphine milligram equivalent
2
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Table 2 Descriptive summary of opioid overdose-related and all-cause healthcare
utilization
Healthcare utilization during the one-year
period following opioid use disorder diagnosis

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

Number of patients who had at least one opioid
overdose, n (%)

144 (2.5)

170 (6.2)

314 (3.7)

0.04 (0.28)
0.01 (0.10)
4.58 (4.29)
0.06 (0.60)
0.03 (0.25)

0.08 (0.35)
0.02 (0.14)
4.42 (6.15)
0.11 (0.61)
0.08 (0.42)

0.05 (0.30)
0.01 (0.11)
4.51 (5.19)
0.07 (0.61)
0.04 (0.31)

0.56 (1.55)
10.91 (17.20)
26.74 (23.60)
2.07 (5.06)

1.22 (1.92)
14.34 (18.57)
35.59 (29.98)
3.02 (6.41)

0.77 (1.71)
12.52 (17.94)
29.61 (26.17)
2.38 (5.55)

Opioid overdose-related healthcare utilization,
Mean (SD)
Number of opioid overdose episodes
Number of inpatient visits
Length of inpatient stay (day)*
Number of outpatient visits
Number of ED visits
All-cause healthcare utilization, Mean (SD)
Number of inpatient visits
Length of inpatient stay (day)*
Number of outpatient visits
Number of ED visits
ED: emergency department.
* The average length of inpatient stay was calculated among patients who had at least one inpatient admission.
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Table 3 Descriptive summary of opioid-related and all-cause healthcare cost per patient
Cost of different healthcare utilization
during one-year following opioid use
disorder diagnosis
Opioid overdose-related cost in US
dollars, Mean (SD)
ED visit cost
BUP-NX cost
Inpatient visit cost
Outpatient visit cost
Total cost
All-cause healthcare cost in US
dollars, mean (SD)
ED visit cost
Prescription cost
Inpatient visit cost
Outpatient visit cost
Total cost

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

54 (539)
3637 (2987)
74 (1227)
215 (2585)
3926 (4498)

194 (1308)
2320 (2281)
138 (2045)
467 (2984)
2925 (5066)

100 (869)
3210 (2845)
95 (1541)
297 (2723)
3601 (4713)

3653 (10455)
7125 (11577)
6657 (28325)
20538 (42623)
34316 (63867)

5516 (12831)
5803 (9638)
14125 (34937)
35575 (57314)
55485 (84874)

4257 (11314)
6696 (11002)
9080 (30823)
25416 (48396)
41183 (72043)

BUP-NX: buprenorphine-naloxone; ED: emergency department.
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Table 4 Comparison of outcomes between early buprenorphine-naloxone initiation
group and late initiation group during the one-year period following the OUD diagnosis
Outcomes

Unadjusted

Adjusted with
complete records

Adjusted with MI

Count of opioid overdose episodes
(RR with 95% CI)

0.45 (0.35, 0.58)

0.52 (0.38, 0.72)

0.58 (0.45, 0.74)

Count of opioid overdose-related
ED visit (RR with 95% CI)

0.36 (0.29, 0.44)

0.43 (0.32, 0.57)

0.49 (0.39, 0.60)

Opioid overdose (OR with 95% CI)

0.39 (0.31, 0.49)

0.44 (0.32, 0.61)

0.52 (0.41, 0.66)

Total healthcare cost (CR with 95%
CI)

0.62 (0.59, 0.65)

0.68 (0.64, 0.72)

0.69 (0.66, 0.72)

RR: risk ratio; CI: Confidence Interval; OR: odds ratio; CR: cost ratio.
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Abstract:
Opioid use disorder (OUD) is a chronic disease requiring long-term treatment and is
associated with opioid overdose and increased risk of mortality. However, existing
randomized clinical trials focused on short-term treatment engagement and
detoxification rather than subsequently long-term overdoses or mortality due to limited
follow-up time and ethical considerations. We constructed a hypothetical trial to assess
the association of time-varying buprenorphine-naloxone during follow-up on opioid
overdose and death by using an administrative claims database. We identified 58,835
insured adult patients with OUD diagnosis in the US, 2010-2017. We fit a marginal
structural model using inverse probability weighting methods to account for measured
baseline and time-varying confounders, as well as selection bias due to possibly
informative loss-to-follow-up. We found that continuous receipt of buprenorphinenaloxone was associated with reduced risk of opioid overdose (hazard ratio (HR) = 0.66,
95% confidence interval (CI): 0.49, 0.91), death (HR= 0.24, 95% CI: 0.08, 0.75), and
overdose or death (HR= 0.58, 95% CI: 0.40, 0.84). The E-value for HR of death was 7.8,
which was larger than the upper 95% CI of the association between each measured
baseline variable and all-cause death in the model, which implies that the unmeasured
confounding itself may not explain the observed estimate of the effect of treatment on
the endpoint of all-cause mortality.
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Introduction

The crisis of drug poisoning death is a major concern in the United States with the
COVID-19 pandemic likely exacerbating this problem (1). According to the National
Institute on Drug Abuse, in 2019 alone, there were 70,630 drug poisoning deaths, out of
which approximately 71% (n = 49,860) were due to opioids and 20% (n = 14,139) were
due to prescription opioids (2). Due to the COVID-19 pandemic, there was an
acceleration of increasing drug overdose deaths started from 2020 March to 2020 May
based on available data (3). Efforts had been made to address this public health issue.
The US Food and Drug Administration (FDA) approved buprenorphine products
(with/without naloxone) as medication for opioid use disorder (MOUD) (4, 5). The
American Society of Addiction Medicine provided a national practice guideline
suggesting prescribing buprenorphine for patients with OUD and the Journal of the
American Medical Association published a clinical guideline for the management of OUD
specifically stated that the buprenorphine-naloxone (BUP-NX) product was the
recommended treatment (6-8).

The benefit of BUP-NX treatment for patients with opioid use disorder is supported by
evidence from clinical trials. One randomized clinical trial compared BUP-NX versus
clonidine on retention and treatment success (negative urine sample test of illicit
opioids) at the end of a 14-day-follow-up (9). The result showed that in both inpatient
and outpatient settings, there were significantly more patients who achieved treatment
33

retention and success among the BUP-NX arm than the clonidine arm. Another
randomized clinical trial compared the timely BUP-NX initiation by emergency
department versus brief negotiation and/or referral on treatment retention, selfreported illegal drug usage, and urine test of illegal drug after 30-day follow-up (10).
This study demonstrated that patients diagnosed with OUD who visited the emergency
department and initiated BUP-NX had significantly higher treatment engagement and
lower illegal drug usage than patients who only received brief negotiation and/or
referral.

Randomized clinical trials thus far have provided evidence supporting the short-term
efficacy of BUP-NX on detoxification. However, opioid use disorder is a chronic disease
requiring long-term treatment and is associated with opioid overdose and increased risk
of mortality (11, 12). The American Society of Addiction Medicine suggested that the
buprenorphine treatment discontinuation should be a slow process with ‘indefinite
duration’ (6). Martin et al. also stated that buprenorphine should be prescribed as long
as it still could benefit the patient (13). In summary, the follow-up time of clinical trials
was limited to 24 weeks at most, while some had a duration of only 14 days. Given the
longer trajectory of this chronic disease and health-related outcomes, previously
conducted clinical trials did not provide information about the real-world effectiveness
of this medication for a long-term period.
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When the randomized clinical trial is not feasible or ethical, as in this instance, the
conceptualization of a hypothetical randomized clinical trial can be used to conduct a
trial emulation using the routinely collected data as best as possible, leveraging the
available information to approximate the key features of the hypothetical trial (14).
There is published evidence that such an approach is achievable by clearly stating
known limitations of the observational data and analytic approach (14, 15). Given the
lack of long-term randomized trial for opioid use disorder management, we aim to
emulate a hypothetical trial that estimates the effectiveness of buprenorphine-naloxone
(BUP-NX) on health outcomes, specifically opioid overdose and all-cause mortality, using
large, routinely-collected observational health data sets.

Study Design

We first designed a conceptual randomized trial and then designed a retrospective
cohort study to emulate the conceptual trial as closely as possible using an
administrative claims data source: the Optum’s de-identified Clinformatics® Data Mart
(OptumInsight, Eden Prairie, MN) from January 1, 2010 to December 31, 2017. Major
protocol elements of the conceptual randomized trial and the rationale, design, and
method for the retrospective cohort study emulating the conceptual trial were provided
in Appendix B Table 1. The target population was insured adults diagnosed with opioid
use disorder (OUD) in the US. We identified patients who had at least two outpatient
claims or one inpatient claim of opioid use disorder as the primary or secondary
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diagnosis. The diagnosis was identified by the International Classification of Disease
9/10th revision, clinical modification (ICD-9/19-CM) code (Appendix B Table 2).

The first eligible OUD diagnosis in the database was defined as the start of study followup (time zero) for that particular patient. The one-year period before time zero was
defined as the baseline period. Patients were followed for up to two years after their
OUD diagnosis. The follow-up ended when outcome occurred, the patient was lost-tofollow-up, or the patient reached the end of the database (December 31, 2017),
whichever happened first. All patients were required to be continuously enrolled in the
database during the baseline period and at least 18-year-old at the time of time zero
and had at least 30-day of follow-up. Patients who had received buprenorphinenaloxone or naltrexone, or who had visited methadone clinics during baseline period
were excluded. Patients who died during baseline period were also excluded. Patients
missing state of residence or gender information were excluded (Figure 1). No
imputation method was applied since the proportion of missing data is negligible
(0.22%). Loss to follow-up was defined: 1) the patient lost insurance coverage; 2) the
patient did not have any claims (medical, confinement, or pharmacy) for 6 months and
in either case, they were considered as lost-to-follow-up at their last encounter (16).

Several existing studies have shown that patients are at a high risk of overdose and
death during the first four-week after treatment cessation (17, 18) and in light of this,
previous retrospective cohort study selected the same monthly frequency to update
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time-varying exposures (19). The exposure of interest was the time-varying status of
receiving any BUP-NX dispensing in each 30-day interval during the follow-up period.
The exposure was identified from pharmacy claims by brand or generic names, which
contain both buprenorphine and naloxone. The exposure status was updated every 30
days based on the date of dispensing and days of supply. The study outcomes were
opioid overdose, all-cause death, and a composite endpoint of both, whichever
occurred first. The opioid overdose event was identified by the ICD-9/10-CM code from
both inpatient/outpatient claims (Supp Table 1). The overdose outcome included both
non-fatal and fatal overdose that received treatment at the hospital. Mortality
information was originated from the Social Security Administrative Death Master File.
Only year and month of death were available in this deidentified claims database.

We identified the following covariates that were known or suspected risk factors for the
outcomes: age, gender, type of insurance, region, type of product, history of opioid
overdose, chronic pain, depression, alcohol use disorder, opioid usage, and Charlson
comorbidity index (CCI) (Appendix B Table 2) (20-22). The CCI score included 17 major
comorbidities (23). This score is widely used to weigh and quantify the burden of cohort
comorbidities and a strong predictor for fatality (24). To adjust for time-varying
confounding, the following variables were derived and updated every 30 days: usage of
benzodiazepine (yes/no), usage of naltrexone products (yes/no), usage of antidepressants (yes/no), visiting methadone clinic (yes/no), chronic pain (yes/no),
depression (yes/no), alcohol use disorder (yes/no), CCI and daily morphine milligram
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equivalence (MME) dose. The daily MME is a standard measure of the total dosage
including different opioids, such as morphine, oxycodone, mono-ingredient
buprenorphine, etc. The conversion factor and formula were provided by the Centers
for Disease Control and Prevention to standardize different types of opioids into
comparable dosages and to calculate the average daily MME of each dispensing (25).

Statistical Methods

Patient baseline characteristics were summarized overall at baseline. Descriptive
statistics were calculated as means with standard deviations for continuous variables
and percentages for categorical ones. The outcomes were analyzed with time-to-event
statistical methodology and relative comparisons were estimated as hazard ratios (HR).
We fit an unadjusted Cox model. The exposure was parameterized as a time-varying
indictor of receipt of any BUP-NX in the 30 day interval (26, 27). Then, we fitted a
marginal structural model (MSM) with inverse probability weights to estimate the
association between time-varying BUP-NX dispensing on three outcomes: (1) opioid
overdose; (2) death; (3) opioid overdose or death among patients with OUD. If the
identification, exchangeability, and positivity assumptions are met, the estimated effect
from this model can be interpreted as a causal hazard ratio comparing the hazard of
overdose among those who had been continuously receiving BUP-NX during follow-up
to those who never received BUP-NX during follow-up(15, 28). We employed an inverse
probability of treatment weights (IPTW) to adjust for measured time-varying covariates
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to control for confounding as well as the treatment history and also included an inverse
probability of censoring weights (IPCW) to address possible selection bias due to
differential loss to follow-up (29, 30). Essentially, this weighting approach creates a
pseudo-population of the defined treatment strategy (always receiving treatment versus
never receiving treatment) in which no one was lost to follow-up (15, 31). The stabilized
IPTW and IPCW were estimated by two separate pooled logistic regression models.
Baseline variables, time-varying variables, and treatment history were included in
calculating the denominator of treatment weights. Baseline variables were included to
calculate the numerator of treatment weights. Treatment was included in calculating
the censoring weights (31). Using a stabilized weight in the outcome model may be
more efficient in this setting (15, 28). We fit a flexible function of time (measured in
months since OUD diagnosis) using cubic splines with four knots (31, 32). The same set
of baseline variables was also included in the outcome model (31). We used robust
standard errors for parameter estimates to obtain Wald-type confidence intervals (29,
31). We calculated the E-values for the HRs to quantify the robustness of the results to
the no unmeasured confounding assumption (33-35).

In the sensitivity analysis, we used an alternative loss-to-follow-up definition established
by Lesko et al. (16). This alternative definition may be more appropriate when outcome
information is obtained from an external source, such as a death registry. After the last
encounter of patients, we carried forward their information for six additional 30-day
intervals and calculated the corresponding hazard ratios (HRs). All statistical analysis
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was done by SAS 9.4 (SAS Institute, Cary, NC) and all statistical tests were two-sided and
conducted at the 0.05 significance level.

Results

We successfully identified 58,835 adult patients diagnosed with opioid use disorder
from 2010 to 2017. Approximately half of the patients were male (49%) and the mean
age of the analytical sample was 51 years (SD = 17.6). Among all patients, 55% were
enrolled in commercial insurance and the others were enrolled in Medicare Advantage.
Most patients used the health maintenance organization or point of service as their
insurance product (69%). During the one-year baseline period, the overall disease
burden measured by the CCI was 1 (SD = 1.64), which means that on average patients
had one out of the seventy comorbidities included in CCI. A small proportion of patients
had a documented history of opioid overdose (4%) and 15% had documented alcohol
use disorder. Almost half of the patients had depression (47%) and more than twothirds of patients had chronic pain conditions (79%) (Table 1).

The total person-time for opioid overdose, death, and composite endpoint were 63,910
person-years, 65,180 person-years, and 63,881 person-years, respectively. During the
study follow-up, 1,908 (3.2%) patients had at least one opioid overdose, 1,051 (1.8%)
patients died, and 2,874 (4.9%) patients experienced the composite endpoint of either
death or opioid overdose during the follow-up. There were 5,722 patients who had
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received at least one BUP-NX dispensing before having an opioid overdose or being lostto-follow-up. For the other two endpoints: death and composite, there were 5,835, and
5,720 patients who had at least one BUP-NX dispensing during the follow-up,
respectively. We focused on discussion on results from the MSM that accounted for
measured baseline and time-varying confounding and lost-to-follow-up and offered a
more appealing interpretation (Table 2). Patients who continuously received BUP-NX
during follow-up had a 34% lower hazard of overdose (adjusted hazard ratio (aHR) =
0.66, 95% confidence interval (CI): 0.49, 0.91), a 76% lower hazard of death (aHR = 0.24,
95% CI: 0.08, 0.75), and a 42% lower hazard of the composite endpoint (aHR = 0.58, 95%
CI: 0.40, 0.84) during follow-up, as compared to patients who were not on treatment for
the duration of follow-up. The adjusted survival curves (with inverse probability
weights) for each of the three endpoints (36) were provided in Appendix B Figure 1 to 3.
The never exposure patients had higher estimated cumulative incidence of opioid
overdose or death than patients who were continuously treated. The mean weights
were close to 1 which suggests no evidence of model misspecification or positivity
assumption violation (15). The E value for estimated HRs of three outcomes: opioid
overdose, death, and composite endpoint, were 2.4, 7.8, and 2.8, respectively (Table 2).

In the sensitivity analysis, the average follow-up time was longer and more events were
observed for all three endpoints in the sensitivity analysis than the main analysis (Table
2 and Appendix B Table 3). The aHRs estimated from the sensitivity analysis for opioid
overdose, death, and composite endpoint were 0.73 (95% CI: 0.55, 0.96), 0.45 (95% CI:
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0.22, 0.92), and 0.69 (95% CI: 0.53, 0.90). The point estimators were similar to the main
analysis, but were attenuated towards the null, likely due to longer the follow-up with
few additional events.

Discussion

In this retrospective cohort study, we estimated the association of time-varying BUP-NX
dispensing on subsequent opioid overdose and/or death with an application of causal
inference methods under a trial emulation framework using routinely-collected health
data. The data source is a large national administrative claims database from 2010 to
2017 and included 58,835 patients diagnosed with opioid used disorder (OUD) in the
United States. A marginal structural model was applied to analyze the time-to-event
outcomes and to make inferences from an observational setting. With adjustment for
measured baseline and time-varying variables and selection bias due to possibly
informative lost-to-follow-up, we found that continuously receiving BUP-NX for the
duration of two-year follow-up could decrease the hazard of opioid overdose and/or
death among patients who were diagnosed with OUD, as compared to those who had
never received BUP-NX during follow-up.

Medication treatment retention or sustained medication treatment has been shown to
be one of the most important protective factors associated with a lower risk of opioid
overdose. Furthermore, the risk of overdose after treatment discontinuation is high
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regardless of the treatment duration before discontinuation (37). Chang et al. used the
Maryland prescription drug monitoring program (2015 to 2016) to investigate protective
and harmful risk factors for nonfatal opioid overdose. Their results demonstrated that
an additional 100-day buprenorphine treatment was associated with a 36% reduction of
risk of opioid overdose among patients with opioid use disorder and received at least
one buprenorphine dispensing (odds ratio = 0.64, 95% CI: 0.60, 0.69) (38). Another study
conducted by Morgan et al. used a Cox model with a time-varying exposure and
adjusted for baseline confounding found that receiving buprenorphine dispensing was
associated with a lower hazard of opioid overdose (adjusted HR = 0.40, 95% CI: 0.35,
0.46), compared to not receiving treatment (39). Larochelle et al. focused on adult
patients, who had already experienced a nonfatal opioid overdose, used the timevarying Cox regression model and found that buprenorphine treatment was associated
with lower all-cause mortality (adjusted HR = 0.63, 95% CI: 0.46, 0.87) and lower opioidrelated mortality (adjusted HR = 0.62, 95% CI: 0.41, 0.92), compared to no medication
treatment (19).

This study provides new insights by considering the following improvement in study
design and statistical methodology. Conditioning on treatment initiation leads to a
depletion of potential patients who comprise an important part of the target population
of all insured adult patients diagnosed with OUD. This could distort the study sample
from the target patient population of interest, rendering questions among the entire
patient population with OUD difficult to address. Consequently, the finding otherwise
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would be limited to patients who had both the disease and had received a certain level
of treatment. The eligibility criteria to identify the target patient population and
definition of the start of follow-up in this study were carefully designed based on the
concept of trial emulation for an ideal randomized study to address this research
question (14). In the real-world setting, patients with OUD who sought care are not
guaranteed to receive pharmacological treatment after their diagnosis (40, 41). Taking
this into consideration, instead of conditioning on medication treatment initiation, we
included all insured adult patients who had been diagnosed with OUD regardless of
initiation status. Thus, our study population may better approximate the target
population of the insured adult patients with OUD, whom physicians would likely
encounter in clinical practice.

From a statistical method perspective, the time-dependent Cox model can be subject to
bias when the time-dependent confounders are also affected by previous exposure, and
g-methods are needed to properly adjust for time-varying confounding (29, 31). We
applied a marginal structural model (i.e., a g-method) to properly adjust for baseline
(age, gender, regional, opioid overdose, depression, alcohol use disorder, chronic pain,
and CCI) and time-varying confounding (treatment, treatment history, depression,
alcohol use disorder, chronic pain, CCI, anti-depressant, benzodiazepine, methadone
clinic visit, naltrexone, and MME) and possible selection bias due to differential loss-tofollow-up. This method provides valid estimates of the effect of a time-varying
treatment, while also accounting for time-varying confounding, which might be affected
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by treatment history (42). Most importantly, our study employed all available data
sources and appropriate causal inference methods to best quantify the causal effect of
continuously receiving BUP-NX on subsequent opioid overdose and/or death using
routinely-collected data to address a question for which a randomized trial is no longer
ethical or feasible.

We conducted a sensitivity analysis for the definition of lost-to-follow-up (16). Suppose
the outcome was from an external source, which is different from the source for
exposure and other variables. In that case, it should be considered as ‘captured’
information and carried-forward until the end of the period corresponding to the lossto-follow-up definition (six months in our study). In the sensitivity analysis, the average
follow-up time was longer and the number of events observed was larger than the main
analysis due to the loss-to-follow-up definition. The point estimates of HRs from the
MSM for opioid overdose and composite outcomes were comparable between two
different scenarios for the censoring mechanisms.

To make inferences based on results from an observational study, the conditional
exchangeability assumption needs to be held (i.e., given the measured fixed and timevarying variables, the assigned treatment is independent of the counterfactual
outcomes). This assumption cannot be tested with the observed data (15), however,
sensitivity analyses can be conducted. We calculated the E-value for each outcome (43).
The E-value for the outcomes of opioid overdose, death, and composite endpoint were
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2.4, 7.8, and 2.8, respectively. If there were any unmeasured confounders that violated
the conditional exchangeability assumption and biased point estimate of the effect, the
hazard ratio quantifying the association between the unmeasured confounder and
exposure or outcomes must be at least as strong as the E-values indicated above. We
include most known risk factors for opioid overdose and death that were measurable in
these data sets, and the calculated E-value was relatively large compared to the
estimates for the relationship between measured covariates and the outcomes.
Particularly for the outcome of death, the E-value is much larger than the upper 95% CI
for any measured baseline variables included in the model (Appendix B Table 3). Based
on this finding, unmeasured confounding may not completely explain away the
observed effect of treatment on the endpoint of all-cause mortality.

This study has several limitations. Giving the nature of observational studies without
randomly assigned intervention, there could be unknown and/or unmeasured
confounding. In our study, there is no information about OUD severity, illegal drug
usage, community naloxone distribution, and socioeconomic status variables (e.g. race,
education level, income level), which could also be important confounders. Although we
checked usual assumptions for model fit, the results also depend on the model being
correctly specified. There could be measurement error using diagnosis codes in claims
data (44). The endpoint of opioid overdose alone fails to capture nonfatal opioid
overdose events that happened outside of a hospital. To account for this concern, we
built a composite endpoint of opioid overdose or death, which could capture
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fatal/nonfatal opioid overdose in the hospital, fatal opioid overdose outside the
hospital, and death due to other causes. The Death Master File does not capture all
deaths, and actually records fewer death events than actually occurred; this, however,
would bias our result towards the null (45). We want to acknowledge that this study
result should only be generalized to the target patient population included in this study,
which was insured patients (at least 18 years old) diagnosed with opioid use disorder,
who had not received buprenorphine, naltrexone, or methadone during the one-year
period prior to study follow-up, who had at least 30-day of follow-up, and who were
covered by commercial insurance or Medicare Advantage. The data source does not
have enrollees of Medicaid or uninsured patients with OUD and these other groups
represent distinct patient populations for which these results may not generalize.

In summary, we designed a retrospective cohort study using the routinely-collected data
to emulate a hypothetical randomized trial, which estimates the effect of continuously
receiving BUP-NX dispensing versus never receiving BUP-NX on opioid overdose and allcause mortality. With a well-defined population and treatment strategy, equitably
assigned time horizon across exposure groups, application of a marginal structural
model, and sensitivity analyses to modeling assumptions, the association could
potentially confer a causal interpretation in the target patient population. We quantified
the strength and robustness of the association by calculating the E-value. Our study
provides evidence of the effectiveness of continuously buprenorphine-naloxone
treatment against opioid overdose and/or death.
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Figure 1 Flowchart of analytical sample building for the retrospective cohort study of
patients with opioid use disorder in the United States, 2010 - 2017
175,426 patients had been
diagnosed with OUD during 2010 2017

75,034 were at least 18 years old
and had been continuously
enrolled for baseline period.

130 patients were excluded due
to missing state of residence or
gender.
106 patients were excluded
they died during baseline or
first 30 days of follow-up

66,697 patients did not have
buprenorphine-naloxone or
naltrexone and did not visit
methadone clinics during baseline
period.

7,626 patients lost-to-follow-up
or censored during the first 30
days of follow-up

58,835 patients included in
the analysis
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Table 1 Descriptive summary of baseline demographic, medication, and comorbidity
information of eligible patients with opioid use disorder
Baseline characteristics

Overall cohort
(n = 58,835)

Age (years) at beginning of follow-up, Mean (SD)

51 (17.6)

Gender, n (%)
Female
Male
Region, n (%)
Midwest
Northeast
South
West

30114 (51.2)
28721 (48.8)
10615 (18.0)
7361 (12.5)
26267 (44.7)
14592 (24.8)

Insurance type, n (%)
Commercial
Medicare Advantage
Insurance product, n (%)*
Exclusive provider organization
Health maintenance organization
Point of service
Preferred provider organization
Others

32551 (55.33)
26284 (44.67)

3749 (6.4)
16095 (27.4)
24639 (41.9)
3484 (5.9)
10868 (18.5)

Medical conditions during baseline period, n(%)

Chronic pain
Depression
Opioid overdose
Alcohol use disorder
CCI at baseline, Mean (SD)
CCI = Charlson comorbidity index.

46559 (79.13)
27847 (47.33)
2345 (3.99)
9011 (15.32)
1 (1.64)

*Values of polytomous variables might not sum to 100% due to rounding
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Table 2 Total person-time and estimated hazard ratios (HRs) with 95% confidence
intervals (CIs) of continuously receiving BUP-NX dispensing versus not receiving BUP-NX
on three different outcomes
Parameter

Endpoint:
First opioid
overdose

Death

Composite
endpoint

63910.6

65180.2

63881.6

1.086
1908 (3.24)

1.167
1051 (1.79)

1.086
2874 (4.88)

5722 (9.73)

5835 (9.92)

5720 (9.72)

0.71 (0.56, 0.88)

0.11 (0.05, 0.23)

0.50 (0.40, 0.62)

Weighted total person-time, unit:
person-year

64906

66897.5

65183.76

Average weighted follow-up time,
unit: year

1.10

1.14

1.11

Weighted number of events, n
HR (95% CI)

1904
0.66 (0.49, 0.91)

1059
0.24 (0.08, 0.75)

2874
0.58 (0.40, 0.84)

Mean Weight

1.02

1.03

1.02

E-value

2.4

7.8

2.8

Unadjusted model
Total person-time, unit: personyear
Average follow-up time, unit: year
Number of events, n (%)
Patients received at least one
BUP-NX during follow-up, n (%)
HR (95% CI)
Marginal structural model
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Abstract
Background:
Buprenorphine-naloxone (BUP-NX) is a recommended pharmacological treatment for
opioid use disorder (OUD). Patients with OUD may influence each other’s health
outcomes due to a shared prescriber, medication diversion, and possible geographical
proximity. This is referred to as dissemination. We aimed to quantify the possible
disseminated effects of BUP-NX on outcomes: opioid overdose, all-cause mortality,
emergence department admission, and hospitalization among patients with OUD.
Methods:
This study was a retrospective cohort study using administrative claims data in the
United States, 2010 – 2017. The analytical sample included 2,831 patients who formed
885 unique clusters (patients sharing the same prescriber). The proportion of exposed
patients was defined as coverage. The Hájek-type stabilized estimator was applied to
estimate two causal effects: direct (comparing the treated patients to untreated, at a
certain coverage level); disseminated (comparing the untreated patients between
clusters contrasting two coverage levels).
Result:
Among 33% BUP-NX coverage clusters, patients who received BUP-NX had 28.1% lower
risk of opioid overdose (direct effect in relative risk (RR) = 0.719, 95% confidence
interval (CI): 0.302, 1.136) compared to untreated patients. Compared to the untreated
patients in 33% coverage clusters, the untreated patients in 67% coverage clusters had
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38.7% lower risk of opioid overdose (disseminated effect in RR = 0.613, 95% CI: 0.334,
0.892).
Conclusions:
Increasing access to BUP-NX could not only protect patients who were diagnosed with
OUD and received the medication, against opioid overdose, all-cause mortality, and allcause hospitalization, but might also benefit patients who did not receive the
medication themselves but shared the same prescriber.

59

Introduction

Buprenorphine-naloxone product is one of the three medications approved by the US
Food and Drug Administration for opioid use disorder (OUD) management and is a
recommended treatment as long as there is no contraindication (1-3). Randomized
clinical trials demonstrated that patients who were randomized to buprenorphine
treatment had better treatment engagement and retention than other alternatives
(clonidine or non-pharmacological treatments) (4, 5). Meanwhile, observational studies
showed that receiving buprenorphine products was associated with a lower risk of
opioid overdose, lower risk of all-cause death, and lower healthcare utilization
(hospitalization, total healthcare cost ) (6-9). Among all these studies, one common and
often ignored assumption embedded in the treatment definition was the stable unit
treatment value assumption (SUTVA), which assumed that one individual’s treatment
would not affect others’ outcomes (10, 11). Treatment dissemination (or interference)
occurs when the treatment received by one individual influences not only that person
but also other individuals in the study (12, 13). The SUTVA assumption may not hold in
the setting of pharmacological opioid use disorder management. In addition to the
effect of treatment on patients who received it themselves, patients could share the
medication (also known as medication diversion) (14) and could exert social influence
on each other’s treatment preferences and subsequent health outcomes due to shared
healthcare providers and potentially also shared geographical proximity (15-17).
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One potential mechanism of treatment dissemination among patients with OUD was
through medication diversion. Diversion of buprenorphine products for detoxification or
reducing withdrawal symptoms occurred among patients who were prescribed
buprenorphine for OUD (18, 19). One study in 2016 reported 101 out of 200 (50.5%)
patients had self-reported buprenorphine sharing behavior in Massachusetts (20). A
survey study conducted in Baltimore, Maryland showed participants who reported using
diverted methadone had reported less heroin and cocaine usage in the past 30 days
(21). In addition, we hypothesize another potential disseminated effect mechanism:
patients sharing the same healthcare provider might also share geographical proximity,
which could potentially have peer-education behavior and might have a positive
influence on social norms. Peer influence and education might promote healthbeneficial behavior and confidence in receiving care from the healthcare provider, which
has been shown to be correlated with better health outcomes and quality of life (22). To
quantify the potential disseminated effect, we designed a retrospective cohort study
and employed causal inference methods to evaluate possible treatment dissemination
among patients with opioid use disorder engaged in care using claims data.

Study Design

We designed a three-period retrospective cohort study using the Optum’s de-identified
Clinformatics® Data Mart (OptumInsight, Eden Prairie, MN, USA) from January 1, 2010,
to December 31, 2017. The study population was defined as adult patients diagnosed
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with opioid use disorder (OUD) in the US. We identified patients with at least two
outpatient claims or one inpatient claim of OUD as the primary or secondary diagnosis.
The first eligible OUD diagnosis in the database was defined as the index date. The oneyear period before the index date was defined as the baseline period. A 90-day window
after the index date was defined as the index period to identify exposure status and
used to determine patient clusters (Figure 1).

The index period was used to categorize the exposure status. In this study, we defined
the exposure as buprenorphine-naloxone (BUP-NX) prescriptions, including all brand
and generic names containing both buprenorphine and naloxone. We established an
algorithm to assign patients to unique prescriber clusters based on their pharmacy
claims during the index period. We first divided pharmacy claims into three hierarchies
based on the medication types: (1) BUP-NX prescriptions; (2) other opioid prescriptions;
(3) all other prescriptions. We selected the prescriber who issued the most prescriptions
for each patient as their main prescriber. For instance, we considered the prescriber
who issued the most number of BUP-NX dispensing as the patient’s main prescriber. If
no BUP-NX dispensing occurred, we then considered opioid prescriptions.) To break a tie
between prescribers, we chose the most recently visited one. Patients who shared the
same main prescriber during the index period were considered in the same cluster. To
have the possibility of a disseminated effect, clusters that only had one patient and
clusters in which no one received BUP-NX were excluded. We defined a two-level
exposure: individual-level BUP-NX defined as the patient receiving more than seven
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days of BUP-NX supply during the index period; the cluster-level BUP-NX coverage was
defined as the proportion of patients in a cluster who received more than seven days of
BUP-NX supply during the index period.

The follow-up period to ascertain outcomes began at the end of the index period (Figure
1). All patients were required to be continuously enrolled during both the baseline and
the index period. We excluded patients who received BUP-NX or naltrexone or visited
methadone clinics during baseline period. Patients who experienced opioid overdose or
died during the baseline or index period were also excluded. The proportion of patients
missing baseline information (gender or state of residence) was negligible (less than
0.2%) and thus were excluded. An additional exclusion criterion was aimed to increase
the chance that patients within a given cluster had overlap in terms of their receipt of
care from the main prescriber. To achieve this, we required patient follow-up in the
same cluster to have overlap with each other during a dynamic two-year time window
(i.e., all patients in a given cluster had OUD diagnosis within two calendar years). The
flowchart that defines the analytic sample is provided in Figure 2.

The outcomes of this study included: opioid overdose (yes/no), all-causal mortality
(yes/no), opioid overdose or death (yes/no), all-cause inpatient admission (yes/no), allcause emergency department (ED) visit (yes/no) during the follow-up period. Opioid
overdoses were identified by the ICD-9/10-CM code from both inpatient/outpatient
claims. The dataset provides all-casual mortality with only year and month, which
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originated from the Social Security Administrative Death Master File. Inpatient
administration was derived based on inpatient claims. We used the Yale ED
identification algorithm combined with the place of service identifier available in the
Optum database to derive the dichotomized variable of any ED visit during follow-up
(23, 24).

We identified the following factors that are possibly associated with opioid overdose or
death: age, gender, type of insurance (commercial or Medicare), type of product,
baseline Charlson comorbidity index (CCI), high dose of opioid during index period,
depression during baseline, alcohol use disorder during baseline, chronic pain during
baseline, antidepressant use during index period, and benzodiazepine use during index
period (25). The daily morphine milligram equivalence (MME) is a standardized
measurement to calculate the dosage of opioids, and the conversion factor is provided
by the Centers for Disease Control and Prevention (26). Daily MME more than 90 mg
was considered as high dose (27) (all opioids were included in the calculation except
BUP-NX). The CCI is widely used to quantify the burden of comorbidities, and it is a
strong predictor of all-cause mortality (28). Comorbidity information was identified by
the International Classification of Disease 9/10th revision, clinical modification (ICD-9/19CM) code (Appendix C Table 1) (29-31).

Statistical Methods
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Baseline characteristics were summarized by the exposure status during the index
period. Descriptive statistics were calculated as mean with standard deviation (SD) for
continuous variables and frequency (with percentage) for discrete variables. We applied
two estimators to estimate causal effects: Inverse probability weighted estimator (IPW
estimator) (32); Hájek-type stabilized weighted estimator (Hájek estimator) (33). Four
causal effects were calculated: direct, disseminated, total, and overall effect. The direct
effect compares the outcomes of exposed individuals with unexposed ones under the
same exposure coverage level. The disseminated effect compares the outcomes of
unexposed individuals under different coverage levels. The total effect combines direct
and disseminated effects comparing exposed patients to unexposed patients under
different coverage levels. The overall effect marginalizes over the individual-level
exposure and compares groups with two different exposure coverage levels (34, 35). We
selected the coverage levels (33%, 50%, 67%) for the comparison to ensure there would
be sufficient information for valid estimation, while providing a meaningful range of
coverage within the cluster.

To quantify these effects, we used a generalized linear mixed effect model with logit link
function and binomial distribution to calculate the cluster-level treatment weights (i.e.,
the group-level propensity score). Then weights were used to calculate group-level
average potential outcomes and to make the contrast between different comparison
groups (32). Our previous work demonstrated that the Hájek estimator tended to have
better performance when the random effect was skewed and deviated from the normal
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distribution, as observed in this setting (manuscript is under review: Buchanan et al.,
Towards Evaluation of Disseminated Effects of Medications for Opioid Use Disorder
within Provider-based Clusters Using Routinely-Collected Health Data). We conducted
variable selection and transformation (age was dichotomized at the sample median) to
fit the group propensity score model to avoid multicollinearity and model convergence
issues (36, 37). Priority was given to variables that were associated with both study
exposure and outcome. At a minimum, the variables included in the propensity score
model were known or suspected risk/protective factors for the outcome and the
association was checked using univariate regression (38).

We conducted sensitivity analysis under three different scenarios: 1) removed the twoyear time window requirement of OUD diagnosis within a prescriber cluster; 2) testing
different individual exposure definition: instead of requiring sever-day of BUP-NX
supply, one day of BUP-NX during index period would be considered as exposed; 3)
testing different variables included in the model: replacing the high MME with any
opioids during index period in the group-level propensity score model. Data cleaning
was conducted using SAS 9.4 (SAS Institute, Cary, NC, USA), and data analysis was
performed using R 3.5.3 (R Core Team 2016). The Hájek estimator used a stabilized
weights for group-level propensity score, which improves the efficiency of the inference
(33). It was calculated using the R package ‘stabilizedinterference’ Version 0.0.2.9200
(39). IPW estimator was calculated using the R package ‘inferference’ Version 1.0.0 (32).
All statistical analyses were two-sided.
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Results

There were 2,831 patients diagnosed with OUD included in the main analytic set.
Overall, there were more males (59.7%) than females (40.3%). The average age is 38
years old (SD = 14.9). Most patients lived in the South (41.0%) and Midwest (24.7%)
region of the United States. Most patients were enrolled in commercial insurance
(84.1%), and the remaining enrolled in Medicare Advantage (16%). Higher coverage
clusters tended to have more patients enrolled in commercial insurance. More than half
of the patients’ insurance product was Point of Service (64.4%). The overall comorbidity
burden measured by the CCI was 1 with SD = 1.33 (i.e., on average, the patient had one
of the 17 chronic comorbidities included in the CCI). One-third of the patients had a
depression diagnosis (32.9%), approximately one-tenth had an alcohol use disorder
diagnosis (8.9%), and more than half had chronic pain diagnosis (52.4%) during the
baseline period. During the index period, one-third of the patients received at least one
dispensing of benzodiazepine (31.7%) and the average daily MME was 22 mg (SD =
52.99) (Table 1).

The final sample (n = 2,831) was clustered by 885 unique main prescribers. The average
cluster size was 3 patients ranging from 2 to 20 patients. Out of these 2,831 patients,
1,743 patients (61.6%) received BUP-NX dispensing with at least 7 days of supply during
the 90-day index period. Among all patients, 95 (3.4%) experienced at least one opioid
overdose during 2-year follow-up period; 67 patients (2.4%) died; 155 patients (5.5%)
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experienced opioid overdose or died; 1,549 patients had at least one emergency
department visit (54.7%); 771 (27.2%) patients had at least one all-cause inpatient
admission (Table 2). The cumulative incidence of all-cause mortality and the composite
endpoint of death and opioid overdose decreased as BUP-NX coverage in the cluster
increased. However, this trend of decreasing crude cumulative incidence was not
observed for the other three outcomes.

We reported the Hájek estimator of direct and disseminated effect on all five outcomes
adjusting for age, gender, CCI, high MME, depression, and use of benzodiazepine in
Table 3. The estimates comparing three different coverage levels of BUP-NX (33%, 50%,
67%) in clusters were calculated as risk difference (RD) with corresponding 95%
confidence intervals (CI). Consider opioid overdose event was rare, we also calculated
relative risk (RR) to quantify the effect on the relative scale. Among clusters with 33%
BUP-NX coverage, patients who received BUP-NX had one fewer opioid overdose per
100 patients (estimated direct RD = -0.014, 95% CI: -0.038, 0.011), compared to
unexposed patients. On the relative scale, there was a 28% reduction in risk of
fatal/non-fatal opioid overdose (estimated direct RR = 0.719, 95% CI: 0.302, 1.136).
Compared to the unexposed patients in low BUP-NX coverage (33%) clusters, the
unexposed patients in high coverage clusters had two fewer opioid overdoses per 100
patients (estimated disseminated RD = -0.019, 95% CI: -0.037, -0.000). On the relative
scale, there was a 39% reduction in the risk of opioid overdose (estimated disseminated
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RR = 0.613, 95% CI: 0.334, 0.892). Forest plots of the Hájek estimator of direct and
disseminated effects were provided in Appendix C Figure 1-4.

The unadjusted estimator and the adjusted IPW estimator were reported in Appendix C
Tables 2 - 11 for the total effect and the overall effect. The total effect, which combined
the direct and disseminated effect, was protective against opioid overdose. Comparing
exposed patients in the high coverage cluster (67%) to unexposed patients in the low
coverage clusters (33%), the estimator of total effect was a 30% reduction in the risk of
opioid overdose (RR = 0.701, 95% CI: 0.375, 1.027) (Appendix C Table 3). The overall
effect marginally comparing patients in high coverage clusters to low coverage clusters
also demonstrated a protective benefit of BUP-NX on opioid overdose (RD = -0.012, 95%
CI: -0.024, 0.001; RR = 0.736, 95% CI: 0.512, 0.960) (Appendix C Tables 2 and 3).

The direction and magnitude of the point estimates demonstrated that the BUP-NX
reduced the risk of all-cause mortality, a composite endpoint of death and opioid
overdose, inpatient visit, and emergency department visit (Table 3 and Appendix C
Tables 2 - 11). However, the estimated effect was small on the absolute scale (RD).
Results of the sensitivity analysis are reported in Supplemental Tables 12 - 16. The Hájek
estimates of four effects were similar across three different scenarios and the main
analysis.

Discussion
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We conducted a retrospective cohort study using a large nationwide claims dataset. We
applied a novel causal inference approach to assess the possible direct and
disseminated effect of treatment. We found that receiving BUP-NX during the index
period was protective against opioid overdose, death, and all-cause hospitalization
during a two-year follow-up, compared to not receiving BUP-NX. Furthermore, patients
who were in a cluster that had a higher coverage level of BUP-NX without receiving the
medication themselves also had a reduction of opioid overdose risk during the followup, as compared with untreated patients in a lower BUP-NX coverage cluster.

A previous study showed that buprenorphine (with/without naloxone) treatment was
associated with a lower risk of overdose among commercially insured patients
compared with no treatment (hazard ratio (HR) = 0.40, 95% CI: 0.35, 0.46) (8). For allcause mortality, a seven-year cohort study in France found that patients who were not
on treatment had a higher risk of death compared to patients who were on
buprenorphine with/out naloxone (HR = 29.0, 95% CI: 10.0 – 84.0) (40). As for healthrelated endpoints, one study found that compared to patients with no medication
treatment, patients who were treated with naltrexone, buprenorphine (with/out
naloxone), or methadone had a similar risk of emergency department visits, but a lower
risk of all-cause inpatient admission (9). Our research extended previous studies in two
major aspects: 1) we assessed the additional benefit of increasing access to BUP-NX due
to possible treatment dissemination within a provider practice; 2) we applied causal
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inference methods to construct a pseudo-population created by group propensity score
methods to adjust for measured baseline confounding. We constructed patient clusters
defined by main prescribers and assessed the possible disseminated effect of BUP-NX
among patients with OUD using administrative claims data. The results could confer a
causal relationship if the following assumptions were satisfied: partial interference
assumption, baseline condition exchangeability, consistency, positivity, no selection bias
due to lost-to-follow-up (13, 35, 41, 42).

There are several limitations of this study. First, due to the limitation of claims data,
there could be unmeasured confounding. For instance, we did not have information
about race, socioeconomic status (e.g. education, income level), illegal drug usage, the
severity of opioid use disorder, and the type of prescribers. Second, diagnosis codes
were obtained from published studies, which may have measurement errors because
diagnosis codes in claims data are not guaranteed to be precise. The Death Master File
did not capture all deaths which would compromise the power and bias the result
towards the null (43). The result also depends on the model being correctly specified.
The individual exposure status was ascertained from the prescription information during
index period without information about adherence during the follow-up period. In the
end, the data source included patients covered by commercial insurance or Medicare
Advantage. The results of this study may only be generalizable to patients diagnosed
with opioid use disorder and who are currently engaged in some level of care with a
prescriber giving medications for OUD in the United States. This was likely the reason
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that the overall exposure coverage level (62%) is much higher than the estimates of
general treatment access (10% - 20%) among people with diagnosed OUD reported by
other studies (44, 45).

To our best knowledge, this is the first study attempting to quantify a possible
disseminated effect of buprenorphine-naloxone on multiple health outcomes using
routinely-collected data. With a well-defined study patient population, two-level
treatment allocation strategy, and accounting for measured baseline confounding, we
found that receiving BUP-NX was protective against opioid overdose, death, and any
inpatient stay during a two-year follow-up, regardless of how many other patients
received the medication. Interestingly, for patients who did not receive BUP-NX
themselves, being in a cluster that had a high coverage level of the medication was
associated with a reduction of risk of opioid overdose and death during the follow-up as
compared with unexposed patients in a lower coverage cluster. Future interventions
and policy changes should be made to further increase the access to BUP-NX treatment,
which would have the potential to benefit both patients receiving the medication and
patients who share the healthcare provider but do not receive the medication.
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Figure 1 Schematic of the retrospective cohort study design
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Figure 2 Flowchart of cohort building based on in/exclusion criteria for a study of
insured adult patients diagnosed with opioid use disorder in the United States during
2010 – 2017
175,426 patients had been
diagnosed with OUD during 2010 2017

65,116 were at least 18 years old
and had been continuously
enrolled for baseline and index
period.

7,074 patients who had MOUD during
baseline were excluded
2,715 patients who experienced opioid
overdose or died during baseline or
index period were excluded

58,843 patients were successfully
assigned to their main
prescribers

92 patients missing gender or state
information was excluded
49,054 patients did not receive
any MOUD during baseline; did
not die or have overdose during
baseline/index period

7,534 patients who had less chance to
interact with others in the same cluster
were excluded.
22,112 patients who formed a oneperson cluster were excluded.
16,485 patients in clusters which had
0% buprenorphine-naloxone
prescribing were excluded.

2,831 patients were included in
the final analysis
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Table 1 Descriptive summary of the demographic and medical history of the study
population who had opioid use disorder (OUD), United States, 2010-2017
BUP-NX coverage during index period

Total

0 - 33%
n = 689

33% - 50%
n= 733

50% - 100%
n = 1409

n = 2831

42 (16.59)

39 (14.89)

36 (13.51)

38 (14.89)

Female

323 (46.9)

279 (38.1)

540 (38.3)

1142 (40.3)

Male

366 (53.1)

454 (61.9)

869 (61.7)

1689 (59.7)

Midwest

124 (18.0)

162 (22.1)

413 (29.3)

699 (24.7)

Northeast

99 (14.4)

101 (13.8)

204 (14.5)

404 (14.3)

South

296 (43.0)

319 (43.5)

545 (38.7)

1160 (41.0)

West

170 (24.7)

151 (20.6)

247 (17.5)

568 (20.1)

Commercial

502 (72.9)

603 (82.3)

1275 (90.5)

2380 (84.1)

Medicare Advantage

187 (27.1)

130 (17.7)

134 (9.5)

451 (15.9)

EPO

53 (7.7)

79 (10.8)

164 (11.6)

296 (10.5)

HMO

117 (17.0)

92 (12.6)

146 (10.4)

355 (12.5)

POS

385 (55.9)

470 (64.1)

969 (68.8)

1824 (64.4)

PPO

48 (7.0)

28 (3.8)

58 (4.1)

134 (4.7)

Others

86 (12.5)

64 (8.7)

72 (5.1)

222 (7.9)

Chronic pain

432 (62.7)

369 (50.3)

682 (48.4)

1483 (52.4)

Depression

229 (33.2)

259 (35.3)

443 (31.4)

931 (32.9)

61 (8.9)
51 (7.4)
1 (1.62)

87 (11.9)
52 (7.1)
1 (1.45)

105 (7.5)
73 (5.2)
0 (1.06)

253 (8.9)
176 (6.2)
1 (1.33)

306 (44.4)
240 (34.8)
40 (72.6)

313 (42.7)
237 (32.3)
21 (51.5)

533 (37.8)
421 (29.9)
13 (38.0)

1152 (40.7)
898 (31.7)
22 (53.0)

91 (85.4)

70 (74.3)

61 (62.4)

74 (75.8)

Age (years) at index date, Mean
(SD)
Gender, n (%)

Region, n (%)

Business unit, n (%)

Product, n (%)

Medical conditions, n (%)

Alcohol use disorder
COPD
CCI at baseline, mean (SD)

Medications usage during index period
Antidepressants, n (%)
Benzodiazepine, n (%)
Mean daily MME, mean (SD)
Mean daily MME among
patients with at least one opioid
prescription, mean (SD)

BUP-NX = buprenorphine-naloxone; SD = standard deviation; EPO = exclusive provider
organization; HMO = health maintenance organization; POS = point of service; PPO =
preferred provider organization; COPD = Chronic obstructive pulmonary disease; CCI =
Charlson comorbidity index; MME = morphine milligram equivalence.
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Table 2 Descriptive summary of cluster-level information and endpoints during two-year
follow-up among different buprenorphine-naloxone (BUP-NX) coverage levels
BUP-NX coverage during index period
0 to 33%
33% to 50%
50% to 100%
n = 689
n= 733
n = 1409
Number of clusters, 130
295
460
n
Size, mean (min,
5 (3, 20)
2 (2, 9)
3 (2, 14)
max)
Overdose, n (%)
22 (3.2)
27 (3.7)
46 (3.3)
Death, n (%)
26 (3.8)
16 (2.2)
25 (1.8)
Composite
44 (6.4)
42 (5.7)
69 (4.9)
endpoint, n (%)
Any ED visit, n (%)
392 (56.9)
387 (52.8)
770 (54.6)
Any inpatient
189 (27.4)
210 (28.6)
372 (26.4)
admission, n (%)
ED = emergency department.
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Total
n = 2831
885
3 (2, 20)
95 (3.4)
67 (2.4)
155 (5.5)
1549 (54.7)
771 (27.2)

Table 3 Estimated Hájek-type stabilized weighted estimators for the direct and
disseminated effects (95% confidence intervals) of receiving buprenorphine-naloxone
among patients with opioid use disorder on five different health outcomes across three
different coverage levels (33%, 50%, 67%)
Outcomes

Effect

Opioid
overdose

DE

IE

All-cause
mortality

DE

IE

Opioid
overdose or
all-cause
mortality

All-cause
emergency
department
visit

All-cause
inpatient
visit

DE

IE

DE

IE

DE

IE

Contrast group:
(α, a)
(33%, 1)-(33%, 0)

Risk difference (95% CI)

Relative risk (95% CI)

-0.014 (-0.038, 0.011)

0.719 (0.302, 1.136)

(50%, 1)-(50%, 0)

0.000 (-0.018, 0.017)

0.988 (0.516, 1.461)

(67%, 1)-(67%, 0)

0.004 (-0.011, 0.019)

1.144 (0.590, 1.698)

(50%, 0)-(33%, 0)

-0.011 (-0.024, 0.002)

0.769 (0.555, 0.982)

(67%, 0)-(33%, 0)

-0.019 (-0.037, -0.000)

0.613 (0.334, 0.892)

(67%, 0)-(50%, 0)

-0.008 (-0.015, -0.000)

0.797 (0.622, 0.972)

(33%, 1)-(33%, 0)

-0.000 (-0.018, 0.017)

0.986 (0.231, 1.740)

(50%, 1)-(50%, 0)

-0.002 (-0.018, 0.014)

0.928 (0.329, 1.527)

(67%, 1)-(67%, 0)

-0.005 (-0.021, 0.012)

0.830 (0.303, 1.357)

(50%, 0)-(33%, 0)

0.002 (-0.008, 0.013)

1.104 (0.628, 1.580)

(67%, 0)-(33%, 0)

0.004 (-0.012, 0.021)

1.196 (0.421, 1.972)

(67%, 0)-(50%, 0)

0.002 (-0.006, 0.010)

1.083 (0.759, 1.408)

(33%, 1)-(33%, 0)

-0.008 (-0.034, 0.019)

0.873 (0.470, 1.275)

(50%, 1)-(50%, 0)

0.000 (-0.022, 0.023)

1.007 (0.616, 1.398)

(67%, 1)-(67%, 0)

-0.000 ( -0.022, 0.021)

0.995 (0.601, 1.390)

(50%, 0)-(33%, 0)

-0.005 (-0.018, 0.008)

0.921 (0.714, 1.127)

(67%, 0)-(33%, 0)

-0.007 (-0.028, 0.014)

0.885 (0.562, 1.208)

(67%, 0)-(50%, 0)

-0.002 (-0.012, 0.008)

0.961 (0.790, 1.132)

(33%, 1)-(33%, 0)

0.010 (-0.049, 0.069)

1.018 (0.910, 1.126)

(50%, 1)-(50%, 0)

0.024 (-0.025, 0.073)

1.044 (0.951, 1.137)

(67%, 1)-(67%, 0)

0.030 (-0.018, 0.079)

1.057 (0.963, 1.151)

(50%, 0)-(33%, 0)

-0.003 (-0.033, 0.026)

0.994 (0.940, 1.047)

(67%, 0)-(33%, 0)

-0.017 (-0.064, 0.030)

0.970 (0.886, 1.053)

(67%, 0)-(50%, 0)

-0.013 (-0.038, 0.012)

0.976 (0.931, 1.020)

(33%, 1)-(33%, 0)

-0.018 (-0.087, 0.050)

0.941 (0.725, 1.158)

(50%, 1)-(50%, 0)

-0.018 (-0.064, 0.029)

0.943 (0.796, 1.090)

(67%, 1)-(67%, 0)

-0.024 (-0.073, 0.026)

0.922 (0.767, 1.077)

(50%, 0)-(33%, 0)

-0.001 (-0.034, 0.031)

0.995 (0.892, 1.099)

(67%, 0)-(33%, 0)

-0.007 (-0.055, 0.041)

0.977 (0.823, 1.131)

(67%, 0)-(50%, 0)

-0.006 (-0.029, 0.017)

0.981 (0.907, 1.056)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = disseminated/indirect effect.
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APPENDICES
Appendix A.
Table 1 ICD-9/10-CM codes for opioid use disorder, opioid overdose, and other
comorbidities
Condition
Opioid use disorder

Version
9

Opioid overdose

10
9
10

Chronic pain

9

10

Depression

9
10

Alcohol misuse

9

10
Chronic pulmonary
disease

9
10

Code
304.00, 304.01, 304.02, 304.03, 304.70,
304.71, 304.72, 304.73, 305.50, 305.51,
305.52, 305.53
F11, F192
965.00, 965.01, 965.02, 965.09, E85.00,
E85.01, E85.02
T40.0, T40.1, T40.2, T40.3, T40.6
(excluding T406.06 and T40.696)
307.80, 307.89, 338.0, 338.2, 338.4,
719.41, 719.45-719.47, 719.49, 720.0,
720.2, 720.9, 721.0-721.4, 721.6, 721.8,
721.9, 722, 723.0, 723.1, 723.3-723.9,
724.0-724.6, 724.70, 724.79, 724.8, 724.9,
729.0-729.2, 729.4, 729.5
F45.4, M08.1, M25.50, M25.51, M25.55 M25.57, M43.2-M43.6, M45, M46.1,
M46.3, M46.4, M46.9, M47, M48.0,
M48.1, M48.8, M48.9, M50.8, M50.9,
M51, M53.1-M53.3, M53.8, M53.9, M54,
M60.8, M60.9, M63.3, M79.0-M79.2,
M79.6, M79.7, M96.1
296.2, 296.3, 296.5, 300.4, 309, 311
F20.4, F31.3–F31.5, F32, F33, F34.1, F41.2,
F43.2
265.2, 291.1–291.3, 291.5–291.9, 303.0,
303.9, 305.0, 357.5, 425.5, 535.3, 571.0–
571.3, 980, V11.3
E52, F10, G62.1, I42.6, K29.2, K70.0,
K70.3, K70.9, T51, Z50.2, Z71.4, Z72.1
416.8, 416.9, 490–492, 494-505, 506.4,
508.1, 508.8
I27.8, I27.9, J40–J44, J46-J47, J60–J67,
J68.4, J70.1, J70.3
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Table 2 Descriptive summary baseline socioeconomic status information of the
analytical sample

Race, n (%)1
Asian
Black
Hispanic
White
Missing
Education, n (%)1
High school diploma or less2
Bachelor’s degree or less
Bachelor’s degree plus
Missing
Household income, n (%)1
<$40K
$40K-$49K
$50K-$59K
$60K-$74K
$75K-$99K
$100K+
Missing
Federal poverty status, n (%)1
Above 400% FPL
Below 400% FPL or missing2
House ownership, n (%)1
Homeowner
Renter
Missing
Personal networth, n (%)1
<$25K
$25K-$149K
$150K-$249K
$250K-$499K
$500K+
Missing
≥ 1 children in household, n (%)1
No
Yes
Missing

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

44 (0.8)
362 (6.4)
323 (5.7)
3841 (67.8)
1097 (19.4)

20 (0.7)
136 (5.0)
137 (5.0)
1876 (68.9)
552 (20.3)

64 (0.8)
498 (5.9)
460 (5.5)
5717 (68.2)
1649 (19.7)

1641 (28.9)
3056 (53.9)
694 (12.2)
276 (4.9)

660 (24.3)
1457 (53.5)
448 (16.5)
156 (5.7)

2301 (27.4)
4513 (53.8)
1142 (13.6)
432 (5.2)

1073 (18.9)
369 (6.5)
330 (5.8)
473 (8.3)
636 (11.2)
1369 (24.2)
1417 (25.0)

433 (15.9)
151 (5.5)
142 (5.2)
194 (7.1)
330 (12.1)
795 (29.2)
676 (24.8)

1506 (18.0)
520 (6.2)
472 (5.6)
667 (8.0)
966 (11.5)
2164 (25.8)
2093 (25.0)

4238 (74.8)
1429 (25.2)

2039 (74.9)
682 (25.1)

6277 (74.8)
2111 (25.2)

3078 (54.3)
652 (11.5)
1937 (34.2)

1529 (56.2)
311 (11.4)
881 (32.4)

4607 (54.9)
963 (11.5)
2818 (33.6)

1568 (27.7)
992 (17.5)
441 (7.8)
584 (10.3)
702 (12.4)
1380 (24.4)

607 (22.3)
474 (17.4)
230 (8.5)
308 (11.3)
450 (16.5)
652 (24.0)

2175 (25.9)
1466 (17.5)
671 (8.0)
892 (10.6)
1152 (13.7)
2032 (24.2)

4220 (74.5)
1183 (20.9)
264 (4.7)

1993 (73.2)
582 (21.4)
146 (5.4)

6213 (74.1)
1765 (21.0)
410 (4.9)

1 Values

of polytomous variables might not sum to 100% due to rounding
Categories were combined, or number was masked due to small cell count
FPL: federal poverty line
2
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Table 3 Patient counts by buprenorphine-naloxone (BUP-NX) initiation date from the
opioid use disorder diagnosis (OUD) day
BUP-NX initiation
date from OUD
diagnosis

Patient
counts

Cumulative
patient counts

Cumulative
percentage

1 - 10
11 - 20
21 - 30
31 - 40
41 - 50
51 - 60
61 - 70
71 - 80
81 - 90
91 - 100
101 - 110
111 - 120
121 - 130
131 - 140
141 - 150
151 - 160
161 - 170
171 - 180
181 - 190
191 - 200
201 - 210
211 - 220
221 - 230
231 - 240
241 - 250
251 - 260
261 - 270
271 - 280
281 - 290
291 - 300
301 - 310
311 - 320
321 - 330
331 - 340
341 - 350
351 - 360
361 - 365

4020
905
742
387
295
253
186
117
117
98
75
61
50
54
66
53
43
54
54
52
48
50
51
52
47
33
41
33
38
51
40
42
48
32
32
47
21

4020
4925
5667
6054
6349
6602
6788
6905
7022
7120
7195
7256
7306
7360
7426
7479
7522
7576
7630
7682
7730
7780
7831
7883
7930
7963
8004
8037
8075
8126
8166
8208
8256
8288
8320
8367
8388

47.9%
58.7%
67.6%
72.2%
75.7%
78.7%
80.9%
82.3%
83.7%
84.9%
85.8%
86.5%
87.1%
87.7%
88.5%
89.2%
89.7%
90.3%
91.0%
91.6%
92.2%
92.8%
93.4%
94.0%
94.5%
94.9%
95.4%
95.8%
96.3%
96.9%
97.4%
97.9%
98.4%
98.8%
99.2%
99.7%
100.0%
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Table 4 Sensitivity analyses using different definitions of early buprenorphine-naloxone
initiation
Outcomes

Main analysis

Sensitivity analysis 1

Sensitivity analysis 2

Number of opioid overdose
episodes (RR with 95% CI)

0.58 (0.45, 0.74)

0.67 (0.52, 0.86)

0.51 (0.40, 0.66)

Number of opioid overdoserelated ED visit (RR with 95% CI)

0.49 (0.39, 0.60)

0.54 (0.43, 0.67)

0.46 (0.38, 0.57)

Any opioid overdose (OR with
95% CI)
Total healthcare cost (CR with
95% CI)

0.52 (0.41, 0.66)

0.58 (0.45, 0.74)

0.47 (0.37, 0.61)

0.69 (0.66, 0.72)

0.74 (0.71, 0.77)

0.67 (0.64, 0.70)

RR: risk ratio; CI: Confidence Interval; OR: odds ratio; CR: cost ratio.
Sensitivity analysis 1: early buprenorphine-naloxone initiation was defined as within 15
days of opioid use disorder diagnosis
Sensitivity analysis 2: early buprenorphine-naloxone initiation was defined as within 45
days of opioid use disorder diagnosis
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Table 5 Sensitivity analyses using different imputation sequences
Outcomes

Main analysis

Sensitivity analysis 3

Sensitivity analysis 4

Number of opioid overdose
episodes (RR with 95% CI)

0.58 (0.45, 0.74)

0.57 (0.44, 0.73)

0.57 (0.44, 0.73)

Number of opioid overdoserelated ED visit (RR with 95%
CI)
Any opioid overdose (OR with
95% CI)
Total healthcare cost (CR with
95% CI)

0.49 (0.39, 0.60)

0.49 (0.40, 0.61)

0.49 (0.40, 0.61)

0.52 (0.41, 0.66)

0.52 (0.41, 0.66)

0.52 (0.41, 0.66)

0.69 (0.66, 0.72)

0.68 (0.65, 0.72)

0.69 (0.65, 0.72)

RR: risk ratio; CI: Confidence Interval; OR: odds ratio; CR: cost ratio.
Sensitivity analysis 3: imputation started from the variable with the least missingness to
the most
Sensitivity analysis 4: imputation started from the variable with the most missingness to
the least
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Table 6 Sensitivity analysis adjusting for the calendar year of opioid use disorder
diagnosis
Outcomes
Number of opioid overdose
episodes (RR with 95% CI)
Number of opioid overdoserelated ED visit (RR with 95% CI)
Any opioid overdose (OR with

Main analysis
0.58 (0.45, 0.74)

Sensitivity analysis 5
0.61 (0.44, 0.78)

0.49 (0.39, 0.60)

0.54 (0.42, 0.69)

0.52 (0.41, 0.66)

0.50 (0.40, 0.62)

0.69 (0.66, 0.72)

0.66 (0.66, 0.72)

95% CI)

Total healthcare cost (CR with
95% CI)

RR: risk ratio; CI: Confidence Interval; OR: odds ratio; CR: cost ratio.
Sensitivity analysis 5: adjusting for the calendar year of opioid use disorder diagnosis as
a categorical variable in the model
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Appendix B.
Table 1 Protocol elements for a conceptual randomized trial of studying the effect of
buprenorphine-naloxone (BUP-NX) versus placebo and the design and method for the
emulation study using routinely collected data
Protocol element Conceptual randomized trial

Retrospective cohort study
(Emulating the conceptual trial using
routinely collected data)

Eligibility criteria Adults living with opioid use disorder
(OUD) between 2010 and 2017 who
have not received pharmacological
treatment for OUD during the year
before screening.

Same as the target trial.
Use medical records and pharmacy claims to
identify patients with OUD who have not
received pharmacological treatment during
the previous year.
Require continuous enrollment for the
screening year to ensure the continuity of the
information.

Treatment arms

Treatment arm: receiving
buprenorphine-naloxone (BUP-NX)
thought the follow-up period; Control
arm: placebo.

The active treatment is defined as the same
as the treatment arm in the target trial.
Placebo is unavailable in the claims data. Not
receiving BUP-NX was defined as comparison.
Use pharmacy claims to derive the BUP-NX
dispensing information.

Treatment
assignment
procedures

After recruitment and screening, eligible Cannot perform randomization.
patients are randomly assigned to either
the treatment arm or the placebo arm. Adjust for measured baseline and prognostic
time-varying variables using statistical
methods.

Follow-up period The follow-up starts at the
Without the milestone of randomization, the
randomization. Patients are followed
follow-up starts at the time when patients are
until endpoint occurs, loss-to-follow-up, first considered as eligible.
or two years after the randomization,
whichever happens first.
Endpoints

1. Opioid overdose; 2. All-cause
mortality.

Same as the target trial.

Causal
parameters of
interest

As-treated effects

Same as the target trial.
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Analysis Plan

Conduct statistical analysis in a time-to- Use time-varying marginal structural models
event manner.
to estimate the effect of the treatment on
endpoints adjusting for treatment dispensing,
Estimate as-treated effect by comparing treatment history, measured baseline and
the hazard of endpoints using treatment time-varying confounders, and selection bias
due to differential loss-to-follow-up.
adherence information adjusting for
pre-specific baseline and prognostic
variables associated with loss-to-followup and treatment adherence will be
adjusted.
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Table 2 ICD-9/10-CM codes for opioid use disorder, opioid overdose, and other
comorbidities
Condition
Opioid use disorder

Version
9

Opioid overdose

10
9
10

Chronic pain

9

Code
304.00, 304.01, 304.02, 304.03, 304.70,
304.71, 304.72, 304.73, 305.50, 305.51,
305.52, 305.53
F11, F192
965.00, 965.01, 965.02, 965.09, E85.00,
E85.01, E85.02
T40.0, T40.1, T40.2, T40.3, T40.6
(excluding T406.06 and T40.696)
307.80, 307.89, 338.0, 338.2, 338.4,
719.41, 719.45-719.47, 719.49, 720.0,
720.2, 720.9, 721.0-721.4, 721.6, 721.8,
721.9, 722, 723.0, 723.1, 723.3-723.9,
724.0-724.6, 724.70, 724.79, 724.8, 724.9,
729.0-729.2, 729.4, 729.5

10

F45.4, M08.1, M25.50, M25.51, M25.55 M25.57, M43.2-M43.6, M45, M46.1,
M46.3, M46.4, M46.9, M47, M48.0,
M48.1, M48.8, M48.9, M50.8, M50.9,
M51, M53.1-M53.3, M53.8, M53.9, M54,
M60.8, M60.9, M63.3, M79.0-M79.2,
M79.6, M79.7, M96.1

Depression

9
10

Alcohol misuse

9

296.2, 296.3, 296.5, 300.4, 309, 311
F20.4, F31.3–F31.5, F32, F33, F34.1, F41.2,
F43.2
265.2, 291.1–291.3, 291.5–291.9, 303.0,
303.9, 305.0, 357.5, 425.5, 535.3, 571.0–
571.3, 980, V11.3
E52, F10, G62.1, I42.6, K29.2, K70.0,
K70.3, K70.9, T51, Z50.2, Z71.4, Z72.1

10
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Table 3 Results from sensitivity analysis with information being carried-forward for six
additional 30-day intervals
Parameter

Endpoint
First opioid
overdose

Death

Composite endpoint

Total person-time, unit: person-

74812.7

76286.8

74713.8

Average follow-up time, unit: year
Number of events, n (%)
HR (95% CI)

1.27
1962 (3.33)
0.71 (0.57, 0.89)

1.30
1330 (2.26)
0.17 (0.10, 0.29)

1.27
3191 (5.42)
0.50 (0.41, 0.61)

Weighted total person-time, unit:
person-year

75417.98

77018.31

75360.20

Average weighted follow-up time,
unit: year

1.28

1.31

1.28

Weighted number of events
HR (95% CI)

1955
0.73 (0.55, 0.96)

1318
0.45 (0.22, 0.92)

3163
0.69 (0.53, 0.90)

Unadjusted model
year

Marginal structural model
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Table 4 The point estimates (with 95% confidence intervals) of measured baseline
variables on each of the three outcomes
Baseline variables

Estimate HR of other baseline variables in the MSM
Overdose

Death

Composite

Age one- year increasing 0.979 (0.976, 0.983)

1.045 (1.039, 1.051)

0.998 (0.995, 1.001)

Gender:
female VS male

1.002 (0.909, 1.105)

0.727 (0.639, 0.826)

0.912 (0.842, 0.989)

History of opioid
overdose: yes VS no

2.932 (2.530, 3.397)

2.336 (1.902, 2.868)

2.712 (2.397, 3.070)

Region:
Midwest VS West

1.148 (0.995, 1.326)

0.831 (0.673, 1.025)

1.062 (0.936, 1.204)

Region:
Northeast VS West

0.966 (0.819, 1.139)

1.252 (1.021, 1.535)

1.045 (0.911, 1.199)

Region:
South VS West

0.805 (0.710, 0.912)

1.026 (0.882, 1.194)

0.858 (0.772, 0.954)

Chronic pain:
yes VS no

0.934 (0.823, 1.059)

0.883 (0.718, 1.087)

0.832 (0.744, 0.930)

Depression:
yes VS no

1.444 (1.302, 1.602)

1.211 (1.062, 1.380)

1.324 (1.217, 1.442)

Alcohol use disorder:
yes VS no

0.986 (0.867, 1.121)

1.608 (1.356, 1.907)

1.131 (1.018, 1.257)

CCI one-unit increasing

1.218 (1.186, 1.251)

1.301 (1.264, 1.340)

1.259 (1.234, 1.285)
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Figure 1 Plot of adjusted cumulative incidence of opioid overdose
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Figure 2 Plot of adjusted cumulative incidence of all-cause mortality
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Figure 3 Plot of adjusted cumulative incidence of the composite endpoint of opioid
overdose and all-cause death
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Appendix C.
Figure 1 Forrest plot for Hájek estimator of the direct effect of buprenorphine-naloxone
on five outcomes on the absolute scale
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Figure 2 Forrest plot for Hájek estimator of the direct effect of buprenorphine-naloxone
on five outcomes on the relative scale
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Figure 3 Forrest plot for Hájek estimator of the disseminated effect of buprenorphinenaloxone on five outcomes on the absolute scale
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Figure 4 Forrest plot for Hájek estimator of the disseminated effect of buprenorphinenaloxone on five outcomes on the relative scale

101

Table 1 ICD-9/10-CM codes for opioid use disorder, opioid overdose, and other
comorbidities
Condition
Opioid use disorder

Version
9

Opioid overdose

10
9
10

Chronic pain

9

Code
304.00, 304.01, 304.02, 304.03, 304.70,
304.71, 304.72, 304.73, 305.50, 305.51,
305.52, 305.53
F11, F192
965.00, 965.01, 965.02, 965.09, E85.00,
E85.01, E85.02
T40.0, T40.1, T40.2, T40.3, T40.6
(excluding T406.06 and T40.696)
307.80, 307.89, 338.0, 338.2, 338.4,
719.41, 719.45-719.47, 719.49, 720.0,
720.2, 720.9, 721.0-721.4, 721.6, 721.8,
721.9, 722, 723.0, 723.1, 723.3-723.9,
724.0-724.6, 724.70, 724.79, 724.8, 724.9,
729.0-729.2, 729.4, 729.5

10

F45.4, M08.1, M25.50, M25.51, M25.55 M25.57, M43.2-M43.6, M45, M46.1,
M46.3, M46.4, M46.9, M47, M48.0,
M48.1, M48.8, M48.9, M50.8, M50.9,
M51, M53.1-M53.3, M53.8, M53.9, M54,
M60.8, M60.9, M63.3, M79.0-M79.2,
M79.6, M79.7, M96.1

Depression

9
10

Alcohol misuse

9

296.2, 296.3, 296.5, 300.4, 309, 311
F20.4, F31.3–F31.5, F32, F33, F34.1, F41.2,
F43.2
265.2, 291.1–291.3, 291.5–291.9, 303.0,
303.9, 305.0, 357.5, 425.5, 535.3, 571.0–
571.3, 980, V11.3
E52, F10, G62.1, I42.6, K29.2, K70.0,
K70.3, K70.9, T51, Z50.2, Z71.4, Z72.1

10
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Table 2 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for opioid
overdose using risk difference across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

0.017 (-0.001, 0.036)

0.012 (-0.012, 0.035)

-0.014 (-0.038, 0.011)

DE: (0.5, 1)-(0.5, 0)

0.012 (-0.003, 0.027)

0.014 (-0.003, 0.03)

0.000 (-0.018, 0.017)

DE: (0.67, 1)-(0.67, 0)

0.009 (-0.006, 0.025)

0.011 (-0.004, 0.026)

0.004 (-0.011, 0.019)

IE: (0.5, 0)-(0.33, 0)

0.000 (-0.005, 0.005)

-0.009 (-0.019, 0.001)

-0.011 (-0.024, 0.002)

IE: (0.67, 0)-(0.33, 0)

0.000 (-0.008, 0.009)

-0.011 (-0.024, 0.002)

-0.019 (-0.037, -0.000)

IE: (0.67, 0)-(0.5, 0)

0.000 (-0.004, 0.004)

-0.002 (-0.006, 0.003)

-0.008 (-0.015, -0.000)

OE: (0.5, 1)-(0.33, 0)

0.012 (-0.003, 0.027)

0.005 (-0.015, 0.024)

-0.007 (-0.017, 0.002)

OE: (0.67, 1)-(0.33, 0)

0.009 (-0.005, 0.023)

0.000 (-0.018, 0.018)

-0.012 (-0.024, 0.001)

OE: (0.67, 1)-(0.5, 0)

0.009 (-0.005, 0.024)

0.009 (-0.006, 0.024)

-0.005 (-0.009, 0.000)

TE: (0.5, a)-(0.33, a)

0.000 (-0.004, 0.004)

-0.006 (-0.013, 0.001)

-0.012 (-0.034, 0.010)

TE: (0.67, a)-(0.33, a)

0.000 (-0.006, 0.007)

-0.007 (-0.017, 0.002)

-0.015 (-0.035, 0.006)

TE: (0.67, a)-(0.5, a)

0.000 (-0.003, 0.004)

-0.001 (-0.005, 0.002)

-0.003 (-0.020, 0.013)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
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Table 3 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for opioid
overdose using relative risk across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)
DE: (0.5, 1)-(0.5, 0)
DE: (0.67, 1)-(0.67, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

1.639 (0.814, 2.464)
1.443 (0.762, 2.123)
1.335 (0.657, 2.013)

1.316 (0.588, 2.044)
1.491 (0.753, 2.230)
1.418 (0.680, 2.156)

0.719 (0.302, 1.136)
0.988 (0.516, 1.461)
1.144 (0.590, 1.698)

IE: (0.5, 0)-(0.33, 0)
IE: (0.67, 0)-(0.33, 0)
IE: (0.67, 0)-(0.5, 0)

1.001 (0.802, 1.199)
1.006 (0.695, 1.317)
1.005 (0.867, 1.143)

0.757 (0.534, 0.980)
0.707 (0.413, 1.001)
0.933 (0.775, 1.092)

0.769 (0.555, 0.982)
0.613 (0.334, 0.892)
0.797 (0.622, 0.972)

OE: (0.5, 1)-(0.33, 0)
OE: (0.67, 1)-(0.33, 0)
OE: (0.67, 1)-(0.5, 0)

1.008 (0.884, 1.131)
1.015 (0.808, 1.222)
1.007 (0.903, 1.111)

0.853 (0.701, 1.006)
0.818 (0.613, 1.022)
0.958 (0.848, 1.068)

0.838 (0.659, 1.016)
0.736 (0.512, 0.960)
0.879 (0.761, 0.996)

TE: (0.5, a)-(0.33, a)
TE: (0.67, a)-(0.33, a)
TE: (0.67, a)-(0.5, a)

1.444 (0.781, 2.106)
1.343 (0.741, 1.945)
1.342 (0.722, 1.963)

1.129 (0.559, 1.700)
1.002 (0.515, 1.490)
1.324 (0.687, 1.960)

0.760 (0.384, 1.136)
0.701 (0.375, 1.027)
0.912 (0.503, 1.320)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
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Table 4 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for all-cause
mortality using risk difference across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

0.012 (-0.006, 0.029)

0.011 (-0.009, 0.031)

0.000 (-0.018, 0.017)

DE: (0.5, 1)-(0.5, 0)

0.008 (-0.005, 0.021)

0.006 (-0.010, 0.022)

-0.002 (-0.018, 0.014)

DE: (0.67, 1)-(0.67, 0)

0.003 (-0.010, 0.016)

0.001 (-0.014, 0.016)

-0.005 (-0.021, 0.012)

IE: (0.5, 0)-(0.33, 0)

-0.004 (-0.009, 0.002)

-0.001 (-0.006, 0.005)

0.002 (-0.008, 0.013)

IE: (0.67, 0)-(0.33, 0)

-0.002 (-0.011, 0.006)

0.001 (-0.009, 0.010)

0.004 (-0.012, 0.021)

IE: (0.67, 0)-(0.5, 0)

0.001 (-0.002, 0.004)

0.001 (-0.004, 0.006)

0.002 (-0.006, 0.010)

OE: (0.5, 1)-(0.33, 0)

0.005 (-0.009, 0.018)

0.005 (-0.011, 0.021)

0.002 (-0.006, 0.009)

OE: (0.67, 1)-(0.33, 0)

0.001 (-0.011, 0.012)

0.002 (-0.013, 0.016)

0.001 (-0.009, 0.012)

OE: (0.67, 1)-(0.5, 0)

0.004 (-0.007, 0.015)

0.002 (-0.012, 0.016)

-0.000 (-0.005, 0.004)

TE: (0.5, a)-(0.33, a)

-0.003 (-0.007, 0.001)

-0.001 (-0.005, 0.003)

0.001 (-0.015, 0.016)

TE: (0.67, a)-(0.33, a)

-0.004 (-0.010, 0.002)

-0.003 (-0.009, 0.004)

-0.000 (-0.015, 0.015)

TE: (0.67, a)-(0.5, a)

-0.001 (-0.004, 0.002)

-0.001 (-0.005, 0.002)

-0.003 (-0.017, 0.012)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
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Table 5 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for all-cause
mortality using relative risk across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

1.548 (0.582, 2.513)

1.526 (0.410, 2.643)

0.986 (0.231, 1.740)

DE: (0.5, 1)-(0.5, 0)

1.466 (0.568, 2.364)

1.271 (0.387, 2.155)

0.928 (0.329, 1.527)

DE: (0.67, 1)-(0.67, 0)

1.159 (0.421, 1.897)

1.043 (0.340, 1.746)

0.830 (0.303, 1.357)

IE: (0.5, 0)-(0.33, 0)

0.835 (0.602, 1.068)

0.976 (0.732, 1.219)

1.104 (0.628, 1.580)

IE: (0.67, 0)-(0.33, 0)

0.884 (0.513, 1.254)

1.027 (0.585, 1.470)

1.196 (0.421, 1.972)

IE: (0.67, 0)-(0.5, 0)

1.059 (0.871, 1.247)

1.053 (0.821, 1.284)

1.083 (0.759, 1.408)

OE: (0.5, 1)-(0.33, 0)

0.870 (0.730, 1.010)

0.943 (0.794, 1.092)

1.069 (0.733, 1.404)

OE: (0.67, 1)-(0.33, 0)

0.827 (0.621, 1.033)

0.899 (0.648, 1.150)

1.066 (0.596, 1.536)

OE: (0.67, 1)-(0.5, 0)

0.950 (0.832, 1.068)

0.954 (0.814, 1.093)

0.998 (0.813, 1.182)

TE: (0.5, a)-(0.33, a)

1.224 (0.525, 1.922)

1.240 (0.397, 2.084)

1.025 (0.318, 1.732)

TE: (0.67, a)-(0.33, a)

1.024 (0.461, 1.587)

1.072 (0.374, 1.770)

0.993 (0.329, 1.658)

TE: (0.67, a)-(0.5, a)

1.227 (0.498, 1.956)

1.098 (0.367, 1.829)

0.899 (0.348, 1.451)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.

106

Table 6 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for the composite
endpoint using risk difference across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

0.028 (0.003, 0.052)

0.024 (-0.004, 0.052)

-0.008 (-0.034, 0.019)

DE: (0.5, 1)-(0.5, 0)

0.018 (-0.001, 0.038)

0.019 (-0.003, 0.041)

0.000 (-0.022, 0.023)

DE: (0.67, 1)-(0.67, 0)

0.010 (-0.009, 0.030)

0.011 (-0.010, 0.032)

-0.000 (-0.022, 0.021)

IE: (0.5, 0)-(0.33, 0)

-0.002 (-0.009, 0.005)

-0.006 (-0.017, 0.004)

-0.005 (-0.018, 0.008)

IE: (0.67, 0)-(0.33, 0)

0.000 (-0.011, 0.011)

-0.005 (-0.020, 0.010)

-0.007 (-0.028, 0.014)

IE: (0.67, 0)-(0.5, 0)

0.002 (-0.003, 0.007)

0.001 (-0.005, 0.007)

-0.002 (-0.012, 0.008)

OE: (0.5, 1)-(0.33, 0)

0.017 (-0.002, 0.036)

0.013 (-0.010, 0.036)

-0.002 (-0.011, 0.007)

OE: (0.67, 1)-(0.33, 0)

0.010 (-0.007, 0.028)

0.006 (-0.015, 0.027)

-0.005 (-0.018, 0.008)

OE: (0.67, 1)-(0.5, 0)

0.012 (-0.005, 0.030)

0.012 (-0.008, 0.031)

-0.003 (-0.008, 0.003)

TE: (0.5, a)-(0.33, a)

-0.002 (-0.007, 0.003)

-0.005 (-0.012, 0.003)

-0.005 (-0.028, 0.019)

TE: (0.67, a)-(0.33, a)

-0.002 (-0.010, 0.006)

-0.006 (-0.017, 0.005)

-0.007 (-0.029, 0.014)

TE: (0.67, a)-(0.5, a)

0.000 (-0.004, 0.004)

-0.001 (-0.006, 0.004)

-0.002 (-0.023, 0.018)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
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Table 7 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for the composite
endpoint using relative risk across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

1.608 (0.966, 2.250)

1.469 (0.811, 2.128)

0.873 (0.470, 1.275)

DE: (0.5, 1)-(0.5, 0)

1.421 (0.883, 1.960)

1.421 (0.836, 2.006)

1.007 (0.616, 1.398)

DE: (0.67, 1)-(0.67, 0)

1.225 (0.735, 1.714)

1.235 (0.717, 1.754)

0.995 (0.601, 1.390)

IE: (0.5, 0)-(0.33, 0)

0.960 (0.810, 1.110)

0.880 (0.690, 1.070)

0.921 (0.714, 1.127)

IE: (0.67, 0)-(0.33, 0)

1.004 (0.762, 1.246)

0.901 (0.624, 1.178)

0.885 (0.562, 1.208)

IE: (0.67, 0)-(0.5, 0)

1.045 (0.934, 1.156)

1.024 (0.891, 1.156)

0.961 (0.790, 1.132)

OE: (0.5, 1)-(0.33, 0)

0.967 (0.877, 1.057)

0.921 (0.804, 1.038)

0.962 (0.812, 1.112)

OE: (0.67, 1)-(0.33, 0)

0.960 (0.813, 1.106)

0.901 (0.733, 1.069)

0.919 (0.708, 1.130)

OE: (0.67, 1)-(0.5, 0)

0.993 (0.915, 1.070)

0.978 (0.893, 1.064)

0.955 (0.856, 1.054)

TE: (0.5, a)-(0.33, a)

1.365 (0.874, 1.856)

1.251 (0.737, 1.764)

0.927 (0.568, 1.285)

TE: (0.67, a)-(0.33, a)

1.229 (0.803, 1.656)

1.113 (0.674, 1.552)

0.881 (0.560, 1.202)

TE: (0.67, a)-(0.5, a)

1.280 (0.809, 1.751)

1.265 (0.763, 1.766)

0.957 (0.610, 1.304)

a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
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Table 8 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for any
emergency visit using risk difference across 3 different BUP-NX coverages (33%, 50%,
67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

0.198 (0.145, 0.252)

0.216 (0.14, 0.293)

0.010 (-0.049, 0.069)

DE: (0.5, 1)-(0.5, 0)

0.119 (0.073, 0.166)

0.147 (0.092, 0.203)

0.024 (-0.025, 0.073)

DE: (0.67, 1)-(0.67, 0)

0.043 (-0.005, 0.091)

0.072 (0.019, 0.125)

0.030 (-0.018, 0.079)

IE: (0.5, 0)-(0.33, 0)

0.004 (-0.019, 0.028)

-0.026 (-0.076, 0.024)

-0.003 (-0.033, 0.026)

IE: (0.67, 0)-(0.33, 0)

0.042 (0.004, 0.080)

-0.001 (-0.066, 0.063)

-0.017 (-0.064, 0.03)

IE: (0.67, 0)-(0.5, 0)

0.038 (0.018, 0.057)

0.025 (-0.001, 0.050)

-0.013 (-0.038, 0.012)

OE: (0.5, 1)-(0.33, 0)

0.124 (0.075, 0.172)

0.121 (0.043, 0.199)

0.006 (-0.018, 0.029)

OE: (0.67, 1)-(0.33, 0)

0.085 (0.039, 0.131)

0.071 (-0.006, 0.148)

0.000 (-0.034, 0.035)

OE: (0.67, 1)-(0.5, 0)

0.080 (0.035, 0.126)

0.097 (0.041, 0.153)

-0.005 (-0.022, 0.011)

TE: (0.5, a)-(0.33, a)

-0.002 (-0.02, 0.016)

-0.025 (-0.064, 0.014)

0.021 (-0.033, 0.074)

TE: (0.67, a)-(0.33, a)

0.005 (-0.022, 0.031)

-0.025 (-0.075, 0.025)

0.014 (-0.039, 0.067)

TE: (0.67, a)-(0.5, a)

0.007 (-0.006, 0.020)

-0.001 (-0.019, 0.018)

0.017 (-0.032, 0.067)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 9 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for any
emergency visit using relative risk across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

1.420 (1.285, 1.554)

1.422 (1.229, 1.616)

1.018 (0.910, 1.126)

DE: (0.5, 1)-(0.5, 0)

1.250 (1.138, 1.361)

1.303 (1.167, 1.439)

1.044 (0.951, 1.137)

DE: (0.67, 1)-(0.67, 0)

1.083 (0.985, 1.181)

1.141 (1.028, 1.255)

1.057 (0.963, 1.151)

IE: (0.5, 0)-(0.33, 0)

1.010 (0.959, 1.060)

0.949 (0.856, 1.042)

0.994 (0.940, 1.047)

IE: (0.67, 0)-(0.33, 0)

1.089 (1.006, 1.172)

0.997 (0.871, 1.123)

0.970 (0.886, 1.053)

IE: (0.67, 0)-(0.5, 0)

1.079 (1.037, 1.121)

1.051 (0.997, 1.105)

0.976 (0.931, 1.020)

OE: (0.5, 1)-(0.33, 0)

0.996 (0.963, 1.030)

0.958 (0.894, 1.022)

1.010 (0.968, 1.053)

OE: (0.67, 1)-(0.33, 0)

1.008 (0.959, 1.058)

0.957 (0.875, 1.039)

1.001 (0.938, 1.063)

OE: (0.67, 1)-(0.5, 0)

1.012 (0.988, 1.037)

0.999 (0.966, 1.031)

0.990 (0.961, 1.020)

TE: (0.5, a)-(0.33, a)

1.262 (1.143, 1.381)

1.236 (1.057, 1.416)

1.037 (0.938, 1.136)

TE: (0.67, a)-(0.33, a)

1.180 (1.070, 1.289)

1.138 (0.971, 1.306)

1.025 (0.927, 1.123)

TE: (0.67, a)-(0.5, a)

1.169 (1.064, 1.273)

1.199 (1.069, 1.330)

1.031 (0.939, 1.124)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 10 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for any inpatient
admission using risk difference across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

0.083 (0.035, 0.131)

0.085 (0.016, 0.153)

-0.018 (-0.087, 0.050)

DE: (0.5, 1)-(0.5, 0)

0.039 (-0.001, 0.079)

0.051 (0.003, 0.098)

-0.018 (-0.064, 0.029)

DE: (0.67, 1)-(0.67, 0)

-0.006 (-0.047, 0.035)

0.004 (-0.041, 0.049)

-0.024 (-0.073, 0.026)

IE: (0.5, 0)-(0.33, 0)

0.006 (-0.013, 0.024)

-0.02 (-0.056, 0.017)

-0.001 (-0.034, 0.031)

IE: (0.67, 0)-(0.33, 0)

0.026 (-0.003, 0.056)

-0.005 (-0.052, 0.042)

-0.007 (-0.055, 0.041)

IE: (0.67, 0)-(0.5, 0)

0.021 (0.007, 0.034)

0.014 (-0.003, 0.032)

-0.006 (-0.029, 0.017)

OE: (0.5, 1)-(0.33, 0)

0.044 (0.003, 0.086)

0.031 (-0.030, 0.092)

-0.005 (-0.028, 0.018)

OE: (0.67, 1)-(0.33, 0)

0.020 (-0.018, 0.059)

-0.001 (-0.059, 0.057)

-0.017 (-0.048, 0.014)

OE: (0.67, 1)-(0.5, 0)

0.015 (-0.023, 0.052)

0.019 (-0.025, 0.063)

-0.012 (-0.026, 0.001)

TE: (0.5, a)-(0.33, a)

-0.002 (-0.016, 0.012)

-0.022 (-0.049, 0.005)

-0.019 (-0.072, 0.034)

TE: (0.67, a)-(0.33, a)

-0.005 (-0.025, 0.015)

-0.030 (-0.064, 0.004)

-0.031 (-0.081, 0.019)

TE: (0.67, a)-(0.5, a)

-0.003 (-0.012, 0.007)

-0.008 (-0.020, 0.004)

-0.029 (-0.074, 0.015)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 11 Unadjusted, adjusted IPW estimator and Hájek estimator of direct,
disseminated, overall, and total effect (with 95% confidence intervals) for any inpatient
admission using relative risk across 3 different BUP-NX coverages (33%, 50%, 67%)
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Unadjusted estimator

Adjusted IPW estimator

Hájek estimator

1.336 (1.114, 1.558)

1.298 (1.017, 1.579)

0.941 (0.725, 1.158)

DE: (0.5, 1)-(0.5, 0)

1.153 (0.981, 1.325)

1.192 (0.994, 1.390)

0.943 (0.796, 1.090)

DE: (0.67, 1)-(0.67, 0)

0.978 (0.830, 1.126)

1.015 (0.852, 1.178)

0.922 (0.767, 1.077)

IE: (0.5, 0)-(0.33, 0)

1.024 (0.947, 1.100)

0.931 (0.812, 1.051)

0.995 (0.892, 1.099)

IE: (0.67, 0)-(0.33, 0)

1.108 (0.984, 1.231)

0.982 (0.817, 1.147)

0.977 (0.823, 1.131)

IE: (0.67, 0)-(0.5, 0)

1.082 (1.028, 1.136)

1.055 (0.986, 1.123)

0.981 (0.907, 1.056)

OE: (0.5, 1)-(0.33, 0)

0.991 (0.941, 1.042)

0.928 (0.848, 1.009)

0.984 (0.910, 1.058)

OE: (0.67, 1)-(0.33, 0)

0.982 (0.908, 1.055)

0.902 (0.802, 1.003)

0.943 (0.845, 1.041)

OE: (0.67, 1)-(0.5, 0)

0.990 (0.956, 1.025)

0.972 (0.931, 1.013)

0.958 (0.915, 1.001)

TE: (0.5, a)-(0.33, a)

1.181 (0.995, 1.367)

1.110 (0.878, 1.342)

0.938 (0.774, 1.103)

TE: (0.67, a)-(0.33, a)

1.083 (0.918, 1.249)

0.997 (0.794, 1.200)

0.900 (0.750, 1.051)

TE: (0.67, a)-(0.5, a)

1.058 (0.904, 1.213)

1.071 (0.897, 1.244)

0.900 (0.750, 1.051)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 12 Sensitivity analysis for Hájek-type estimator (with 95% confidence interval) for
opioid overdose across three different BUP-NX coverages (33%, 50%, 67%) in risk
difference scale
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Without 2-year window
requirement
-0.018 (-0.042, 0.005)

Without minimum 7-day
requirement for BUP-NX
-0.007 (-0.03, 0.015)

Included different
variables in the model*

DE: (0.5, 1)-(0.5, 0)

0.001 (-0.012, 0.013)

0.003 (-0.014, 0.02)

0.001 (-0.019, 0.021)

DE: (0.67, 1)-(0.67, 0)

0.011 (-0.001, 0.024)

0.006 (-0.009, 0.02)

IE: (0.5, 0)-(0.33, 0)

-0.017 (-0.03, -0.004)

-0.008 (-0.02, 0.004)

0.006 (-0.010, 0.022)
-0.013 (-0.027, 0.000)

IE: (0.67, 0)-(0.33, 0)

-0.021 (-0.04, -0.001)

-0.013 (-0.031, 0.005)

-0.022 (-0.042, -0.003)

IE: (0.67, 0)-(0.5, 0)

-0.004 (-0.013, 0.005)

-0.005 (-0.012, 0.002)

-0.009 (-0.017, -0.001)

OE: (0.5, 1)-(0.33, 0)

-0.010 (-0.020, 0.000)

-0.004 (-0.013, 0.005)

-0.008 (-0.018, 0.002)

OE: (0.67, 1)-(0.33, 0)

-0.007 (-0.021, 0.007)

-0.007 (-0.019, 0.005)

-0.014 (-0.027, -0.000)

OE: (0.67, 1)-(0.5, 0)

0.003 (-0.004, 0.010)

-0.003 (-0.008, 0.002)

-0.006 (-0.011, -0.000)

TE: (0.5, a)-(0.33, a)

-0.016 (-0.038, 0.006)

-0.005 (-0.025, 0.016)

-0.013 (-0.037, 0.012)

TE: (0.67, a)-(0.33, a)

-0.009 (-0.031, 0.013)

-0.007 (-0.027, 0.012)

-0.017 (-0.039, 0.006)

TE: (0.67, a)-(0.5, a)

0.007 (-0.007, 0.022)

0.000 (-0.015, 0.016)

-0.003 (-0.021, 0.014)

-0.016 (-0.043, 0.012)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
*Replace high daily morphine milligram equivalence (yes/no) with any opioid (yes/no)
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 13 Sensitivity analysis for Hájek-type estimator (with 95% confidence interval) for
all-cause mortality across three different BUP-NX coverages (33%, 50%, 67%) in risk
difference scale
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Without 2-year window
requirement
0.005 (-0.009, 0.018)

Without minimum 7-day
requirement for BUP-NX
0.003 (-0.013, 0.020)

Included different
variables in the model*
0.000 (-0.016, 0.017)

DE: (0.5, 1)-(0.5, 0)

-0.000 (-0.011, 0.010)

0.002 (-0.014, 0.017)

0.001 (-0.014, 0.016)

DE: (0.67, 1)-(0.67, 0)

-0.008 (-0.021, 0.006)

-0.002 (-0.018, 0.015)

-0.001 (-0.016, 0.014)

IE: (0.5, 0)-(0.33, 0)

0.009 (-0.002, 0.020)

0.003 (-0.006, 0.012)

0.001 (-0.009, 0.012)

IE: (0.67, 0)-(0.33, 0)

0.008 (-0.004, 0.020)

0.005 (-0.011, 0.020)

0.002 (-0.014, 0.018)

IE: (0.67, 0)-(0.5, 0)

-0.001 (-0.01, 0.008)

0.002 (-0.006, 0.010)

0.001 (-0.006, 0.008)

OE: (0.5, 1)-(0.33, 0)

0.007 (-0.002, 0.017)

0.003 (-0.004, 0.009)

0.002 (-0.006, 0.010)

OE: (0.67, 1)-(0.33, 0)

0.001 (-0.006, 0.008)

0.003 (-0.007, 0.012)

0.002 (-0.009, 0.013)

OE: (0.67, 1)-(0.5, 0)

-0.006 (-0.015, 0.002)

0.000 (-0.004, 0.004)

0.000 (-0.004, 0.004)

TE: (0.5, a)-(0.33, a)

0.009 (-0.005, 0.022)

0.004 (-0.010, 0.019)

0.003 (-0.014, 0.019)

TE: (0.67, a)-(0.33, a)

0.000 (-0.009, 0.010)

0.003 (-0.011, 0.017)

0.002 (-0.014, 0.017)

TE: (0.67, a)-(0.5, a)

-0.009 (-0.022, 0.004)

0.000 (-0.014, 0.015)

0.001 (-0.013, 0.015)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
*Replace high daily morphine milligram equivalence (yes/no) with any opioid (yes/no)
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 14 Sensitivity analysis for Hájek-type estimator (with 95% confidence interval) for
composite endpoint across three different BUP-NX coverages (33%, 50%, 67%) in risk
difference scale
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Without 2-year
window requirement
-0.010 (-0.037, 0.017)

Without minimum 7-day
requirement for BUP-NX
0.001 (-0.024, 0.026)

Included different
variables in the model*
-0.009 (-0.038, 0.020)

DE: (0.5, 1)-(0.5, 0)

-0.000 (-0.015, 0.015)

0.006 (-0.015, 0.028)

0.005 (-0.018, 0.028)

DE: (0.67, 1)-(0.67, 0)

0.002 (-0.015, 0.018)

0.004 (-0.018, 0.025)

0.006 (-0.015, 0.027)

IE: (0.5, 0)-(0.33, 0)

-0.004 (-0.018, 0.01)

-0.002 (-0.015, 0.012)

-0.008 (-0.021, 0.005)

IE: (0.67, 0)-(0.33, 0)

-0.008 (-0.03, 0.013)

-0.002 (-0.023, 0.019)

-0.012 (-0.033, 0.008)

IE: (0.67, 0)-(0.5, 0)

-0.004 (-0.014, 0.006)

-0.000 (-0.010, 0.009)

-0.004 (-0.014, 0.005)

OE: (0.5, 1)-(0.33, 0)

-0.001 (-0.011, 0.009)

0.001 (-0.008, 0.011)

-0.003 (-0.012, 0.007)

OE: (0.67, 1)-(0.33, 0)

-0.004 (-0.017, 0.01)

0.000 (-0.013, 0.013)

-0.006 (-0.020, 0.008)

OE: (0.67, 1)-(0.5, 0)

-0.003 (-0.01, 0.005)

-0.001 (-0.007, 0.004)

-0.003 (-0.009, 0.003)

TE: (0.5, a)-(0.33, a)

-0.004 (-0.027, 0.018)

0.005 (-0.018, 0.027)

-0.003 (-0.028, 0.022)

TE: (0.67, a)-(0.33, a)

-0.006 (-0.028, 0.016)

0.002 (-0.019, 0.023)

-0.007 (-0.029, 0.016)

TE: (0.67, a)-(0.5, a)

-0.002 (-0.018, 0.014)

0.003 (-0.016, 0.023)

0.001 (-0.019, 0.022)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
*Replace high daily morphine milligram equivalence (yes/no) with any opioid (yes/no)
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 15 Sensitivity analysis for Hájek-type estimator (with 95% confidence interval) for
any emergency department visit across three different BUP-NX coverages (33%, 50%,
67%) in risk difference scale
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Without 2-year window
requirement
0.055 (0.013, 0.097)

Without minimum 7-day
requirement for BUP-NX
0.018 (-0.042, 0.078)

Included different
variables in the model*
0.007 (-0.056, 0.070)

DE: (0.5, 1)-(0.5, 0)

0.039 (0.006, 0.072)

0.027 (-0.023, 0.076)

0.025 (-0.025, 0.074)

DE: (0.67, 1)-(0.67, 0)

0.044 (0.008, 0.08)

0.032 (-0.016, 0.079)

0.032 (-0.017, 0.082)

IE: (0.5, 0)-(0.33, 0)

-0.007 (-0.032, 0.019)

-0.006 (-0.035, 0.022)

-0.004 (-0.037, 0.028)

IE: (0.67, 0)-(0.33, 0)

-0.022 (-0.059, 0.015)

-0.017 (-0.063, 0.029)

-0.019 (-0.070, 0.032)

IE: (0.67, 0)-(0.5, 0)

-0.015 (-0.036, 0.006)

-0.011 (-0.036, 0.014)

-0.015 (-0.041, 0.011)

OE: (0.5, 1)-(0.33, 0)

-0.006 (-0.027, 0.015)

0.002 (-0.022, 0.025)

0.006 (-0.020, 0.032)

OE: (0.67, 1)-(0.33, 0)

-0.011 (-0.039, 0.016)

-0.002 (-0.036, 0.033)

0.000 (-0.038, 0.039)

OE: (0.67, 1)-(0.5, 0)

-0.005 (-0.021, 0.01)

-0.003 (-0.019, 0.013)

-0.006 (-0.024, 0.012)

TE: (0.5, a)-(0.33, a)

0.032 (-0.006, 0.071)

0.020 (-0.033, 0.074)

0.020 (-0.036, 0.076)

TE: (0.67, a)-(0.33, a)

0.022 (-0.017, 0.062)

0.015 (-0.038, 0.067)

0.013 (-0.044, 0.070)

TE: (0.67, a)-(0.5, a)

0.029 (-0.008, 0.065)

0.021 (-0.028, 0.070)

0.017 (-0.034, 0.069)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
*Replace high daily morphine milligram equivalence (yes/no) with any opioid (yes/no)
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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Table 16 Sensitivity analysis for Hájek-type estimator (with 95% confidence interval) for
any inpatient admission across three different BUP-NX coverages (33%, 50%, 67%) in
risk difference scale
Casual contrast
(α, a)
DE: (0.33, 1)-(0.33, 0)

Without 2-year
window requirement
0.059 (-0.013, 0.131)

Without minimum 7-day
requirement for BUP-NX
-0.014 (-0.074, 0.046)

Included different
variables in the model*
-0.026 (-0.105, 0.052)

DE: (0.5, 1)-(0.5, 0)

-0.015 (-0.106, 0.075)

-0.013 (-0.058, 0.032)

-0.018 (-0.066, 0.030)

DE: (0.67, 1)-(0.67, 0)

-0.013 (-0.057, 0.031)

-0.022 (-0.071, 0.028)

-0.021 (-0.069, 0.026)

IE: (0.5, 0)-(0.33, 0)

0.035 (-0.019, 0.088)

0.003 (-0.025, 0.032)

-0.008 (-0.044, 0.028)

IE: (0.67, 0)-(0.33, 0)

0.026 (-0.015, 0.067)

0.001 (-0.044, 0.046)

-0.016 (-0.069, 0.036)

IE: (0.67, 0)-(0.5, 0)

-0.009 (-0.048, 0.030)

-0.003 (-0.025, 0.02)

-0.009 (-0.032, 0.015)

OE: (0.5, 1)-(0.33, 0)

0.007 (-0.012, 0.026)

0.001 (-0.020, 0.023)

-0.008 (-0.034, 0.017)

OE: (0.67, 1)-(0.33, 0)

-0.003 (-0.024, 0.019)

-0.009 (-0.039, 0.020)

-0.023 (-0.057, 0.012)

OE: (0.67, 1)-(0.5, 0)

-0.010 (-0.027, 0.007)

-0.011 (-0.024, 0.003)

-0.014 (-0.029, 0.001)

TE: (0.5, a)-(0.33, a)

0.019 (-0.038, 0.077)

-0.010 (-0.058, 0.039)

-0.025 (-0.084, 0.033)

TE: (0.67, a)-(0.33, a)

0.013 (-0.031, 0.057)

-0.021 (-0.067, 0.026)

-0.038 (-0.093, 0.017)

TE: (0.67, a)-(0.5, a)

-0.022 (-0.094, 0.051)

-0.024 (-0.068, 0.019)

-0.030 (-0.075, 0.015)

DE = direct effect; IE = indirect effect; TE = total effect; OE = overall effect.
*Replace high daily morphine milligram equivalence (yes/no) with any opioid (yes/no)
a = individual-level BUP-NX during index period (1= yes, 0 = no), α= coverage level of
BUP-NX for the prescriber cluster.
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